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The world’s population is ageing: almost every country in the world is experiencing 
growth in the number and proportion of older persons in their population. In Europe 
and Northern America, it is expected that the number of persons aged 60 years and 
older will rise from 261 million in 2017 to 370 million in 2050, representing 23% and 
32% respectively of the total population living in those countries (Eurostat Statistics 
2017). This increase can be explained by several demographic developments. First, life 
expectancy is increasing due to better hygienic, more prosperity and medical advances. 
Second, the post-war baby boom generation is becoming older. Third, fertility rates are 
declining [1]. The combination of these three demographic developments results in a 
both relative and absolute increase of the older population.
ageing, multimorbidity and geriatric conditions
Ageing results from the accumulation of damage to the body due to internal and ex-
ternal stressors. This accumulated damage affects the functioning of cells and tissues. 
Consequentially, the capacity to maintain the homeostasis in the body is compromised 
which can lead to a higher chance of disease and death [2]. There are several conse-
quences of the ageing process that makes the older patient different from the younger 
patient. First, compared with younger ages, physiology in the older body is different. 
These differences consist, amongst others, of a decreased renal function, liver func-
tion and an altered body composition, which can affect metabolism, distribution and 
clearance of pharmacotherapeutics [3]. Second, with increasing age the prevalence of 
disease increases, resulting in a high proportion of older adults suffering from multiple 
(chronic) diseases. The prevalence of these multiple chronic diseases, or multimorbidity, 
in community-dwelling older adults ranges from 35-65% in patients aged 60-69 years 
to 80-99% in patients aged 80 years and older [4]. Third, a higher age and multimorbid-
ity are associated with the presence of geriatric conditions which are described as ‘a 
collection of symptoms and signs common in older adults not necessarily related to a 
specific disease’, for example, a decreased ability to perform activities of daily living (or 
functional impairment), cognitive impairment, delirium and falls [5, 6]. The combina-
tion of an increase of the number of older adults and an increase of the prevalence of 
multiple diseases in these older patients, it is expected that there will be more health 
care demand by older adults [7].
Geriatric assessment
Another difference between younger and older patients, is the complex relationship 
between the four domains of somatic status, mental functioning, physical functioning 
and social functioning [8].
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Below a short description of what kind of assessment these different domains include.
- Somatic status: physical diseases and disabilities, number of prescribed drugs and 
nutritional status.
- Mental functioning: described by cognitive performance and psychiatric disorders like 
apathy and depression.
- Physical functioning: measured by the level of physical capacity (e.g. gait speed, hand-
grip strength) and the ability to perform ‘normal’ instrumental activities of daily living.
- Social functioning: described by a combination of demographical, religious, racial 
diversities, including wellbeing, socio-economic and household characteristics – and 
the family, network and societal levels.
Taken together, the domains of mental, physical and social functioning characterise the 
total level of functioning of the older patient and next to the somatic status may mark 
the extent of increased vulnerability or ‘frailty’. Frailty is a term widely used to denote 
a multidimensional syndrome of loss of reserves (energy, physical ability, cognition, 
health) that gives rise to an increased risk of health outcomes in response to a stressor 
[9]. There are many operational definitions for frailty such as the Fried Phenotype 
based on physical weakness and wasting [10] or the Frailty Index based on a count of 
accumulated deficits [11]. A way of phenotyping older patients is the use of a geriatric 
assessment (GA). In a GA different domains of somatic status, mental functioning, physi-
cal functioning and social functioning are explored, in order to detect conditions that 
contribute to ‘frailty’.
Challenges in treating older patients
Because of the multimorbidity and the complex interaction between the four domains, 
clinical decision making in older patient can be challenging for clinicians. Treatment 
decisions are usually made based on monodisciplinary clinical guidelines [12], but 
one disease already can have a major impact on the quality life and functioning of the 
older patients and potentially influence and causing disability. Since older individuals 
often suffer from multiple chronic diseases, treatments according to monodisciplinary 
guidelines, focused on the management of a single disease result in impractical and un-
workable treatment schemes [13]. Furthermore, clinical guidelines are generally based 
on clinical studies, from which older people are often excluded, due to exclusion criteria 
based on age, comorbidities, cognitive status and medical history [14]. In addition, when 
older adults are included in the clinical studies [15], they appear not to be representative 
for the general population of older adults [16]. The older adults that are participating in 
clinical studies are relatively in a good physical and mental condition compared to older 
patients consulting general practitioners and medical specialists [17].
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It is known that a higher age and multimorbidity are associated with many adverse 
health outcomes such as disability, institutionalization, poorer quality of life and higher 
rates of side effects after treatment [18]. Components of the comprehensive geriatric 
assessment, for example physical capacity and functional dependency, appeared to be 
predictive for outcomes such as survival in community dwelling older adults [19]. But 
also home and hospital comprehensive geriatric assessment were shown to be consis-
tently effective in predicting several health outcomes, including mortality, disability 
and cognitive functions [20]. However, only few studies have assessed the association 
of a geriatric screening on outcomes in vulnerable older patients with severe diseases, 
such as head and neck cancer, esophageal cancer or end-stage renal disease [20]. It are 
especially these vulnerable older patients with severe diseases in whom treatments can 
have major consequences on outcomes such as disability and quality of life.
outcome measurements
Functional independency and quality of life appear to be important outcomes for 
older adults after treatment. Research conducted in community dwelling older adults 
and in older adults with comorbidities reported that older adults in general give more 
importance to quality of life than length of life [21-23]. However, most clinical studies in 
oncology assess treatment-related outcomes such as disease-free survival and mortality 
[24]. Recently, there is a growing interest in outcome measurements relevant for the 
(older) patient, also called patient-reported outcomes measures (PROMs) and that these, 
next to the treatment-related outcomes, could be taken in to account as an outcome 
of interest in (older) patients [24]. PROMs are defined as: ‘any report of the status of a 
patient’s health condition that comes directly from the patient, without interpretation 
of the patient’s response by a clinician or anyone else’ [25]. More knowledge of these 
relevant outcomes for (older) patients could be an important contribution in order to 
personalize treatment decisions.
This thesis has 3 aims:
I) to quantify the lack of evidence in the literature regarding the reporting of geriatric 
assessment in older adults participating in clinical trials
II) to study the association between geriatric characteristics and adverse health outcomes 
in older patients with severe diseases
III) to assess the determinants of a patient reported outcome measurement in an older 
patient population.
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outline of this thesis
Chapter 2 evaluates what kind of older patients participated in randomized clinical 
trials, and if it is clear for clinicians to which older patients the results can be applied. 
In chapter 3 we study the literature on the association between functional and cogni-
tive impairment, social environment, frailty and as outcome adverse health outcomes 
in older patients with head and neck cancer. Chapter 4 further elaborates on this 
topic but in another patient population by studying the literature on the association 
between functional and cognitive impairment, social environment, frailty and as out-
come adverse health outcomes in older patients with esophageal cancer. In chapter 5, 
we prospectively study the association between geriatric characteristics and one-year 
mortality in older head and neck cancer patients. In another prospective study, chapter 
6 studies the determinants of cognitive function in older patients with end-stage renal 
disease. In chapter 7 we study a patient reported outcome measurement; self-rated 
health (SRH). We identify the determinants of self-rated health (SRH) of older patients at 
presentation at the Emergency Department (ED) and three months after the ED visit. In 
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background To critically assess the external validity of randomized controlled trials 
(RCTs) it is important to know what older adults have been enrolled in the trials. The aim 
of this systematic review is to study what proportion of trials specifically designed for 
older patients report on somatic status, physical and mental functioning, social environ-
ment and frailty in the patient characteristics.
Methods PubMed was searched for articles published in 2012 and only RCTs were 
included. Articles were further excluded if not conducted with humans or only second-
ary analyses were reported. A random sample of 10% was drawn. The current review 
analyzed this random sample and further selected trials when the reported mean age 
was ≥ 60 years. We extracted geriatric assessments from the population descriptives or 
the in- and exclusion criteria.
Results In total 1396 trials were analyzed and 300 trials included. The median of the 
reported mean age was 66 (IQR 63-70) and the median percentage of men in the trials 
was 60 (IQR 45-72). In 34% of the RCTs specifically designed for older patients somatic 
status, physical and mental functioning, social environment or frailty were reported in 
the population descriptives or the in- and exclusion criteria. Physical and mental func-
tioning was reported most frequently (22% and 14%). When selecting RCTs on a mean 
age of 70 or 80 years the report of geriatric assessments in the patient characteristics 
was 46% and 85% respectively but represent only 5% and 1% of the trials.
Conclusion Somatic status, physical and mental functioning, social environment and 
frailty are underreported even in RCTs specifically designed for older patients published 
in 2012. Therefore, it is unclear for clinicians to which older patients the results can be 
applied. We recommend systematic to transparently report these relevant characteris-




Older individuals are often underrepresented in randomized clinical trials (RCTs)[1-3]. 
They are frequently excluded as a result of direct and indirect exclusion criteria based 
on the presence of comorbidities and polypharmacy [4]. For instance, Van de Water et al. 
previously demonstrated that due to exclusion criteria based on age, comorbidities and 
medical history only a maximum of 12% of older breast cancer patients would have been 
suitable to enter breast cancer trials [5]. The consequence is that participants enrolled in 
clinical trials often do not represent the older patients in general medical practice and 
thus threaten the external validity of RCTs in the older patient population [6, 7].
Compared to younger patients, older patients are very heterogenic with respect to 
frailty, mobility, functional capacity, and cognitive function. These different domains can 
be systematically assessed by using geriatric assessments [8]. To critically interpret the 
outcome in RCTs and to allow clinicians to judge to which older patients the outcomes 
can be applied, it is important to know which older adults have been enrolled in the 
trials. In scientific literature, patient characteristics are usually described in the popula-
tion descriptives or in the in- and exclusion criteria section. It is currently unknown how 
patient characteristics with respect to physical, mental and social functioning or frailty 
are reported in RCTs specifically designed for older adults.
Therefore, the aim of this systematic review is to study what proportion of RCTs specifi-
cally designed for older adults report on somatic status, physical and mental function-
ing, social environment and frailty in the patient characteristics.
MeThoDs
study selection
For the present study we used the sample from the previously published systematic 
review by Broekhuizen et al. showing that only 7% of the RCTs published in 2012 were 
specifically designed for older adults [3]. The complete search strategy was published 
previously. In short, a systematic search was conducted to identify RCTs that were 
published in 2012 (n=26,740), and after removing duplicates a random sample was 
drawn (n=2375). Articles were further excluded when it was not written in English, had 
no RCT design, when the study included non-human subjects or reported secondary 
analyses. After applying the exclusion criteria and retrieved full-text, 1369 identified 
articles remained. For the current review we started with the sample of 1369, we defined 
“specifically designed for older patients” as a mean age of trial participants of 60 years 
20 Chapter 2
or older and we included all randomised controlled trials of which the mean age was 60 
years or older.
Data extraction
Items extracted from each study included: publication data (author, year), patient 
characteristics (sample size, median age, percentage of males, disease categories and 
geriatric assessments). Disease category was classified according to the International 
Classification of Diseases (ICD-10) of the World Health Organization (WHO). Two re-
searchers (FvD, IP) extracted the geriatric assessments and in case of disagreement, 
consensus was reached after discussion with a third co-author (SPM).
Geriatric assessments
For all studies we extracted if geriatric assessments were reported in the patient char-
acteristics, which are usually reported in the population descriptives or in the in- and 
exclusion criteria section. The geriatric assessments were classified into five geriatric do-
mains: somatic status, physical functioning, mental functioning, social environment and 
frailty. Somatic status was defined as the presence of assessments of somatic co-morbid 
diseases and polypharmacy. Co-morbid diseases had to be assessed by quantitative 
instruments that measure cumulative disease burden or quantitatively by adding up 
the number of chronic and acute medical illnesses. Polypharmacy had to be assessed by 
validated tools. Physical functioning was defined as assessments of functional perfor-
mance, mobility, and objectively measured physical capacity such as hand grip strength, 
gait speed or balance tests. Mental functioning was defined as assessment of any do-
main within cognition, dementia diagnosis, and mood or depression. Assessments were 
classified to the social environment domain when they depicted information about the 
social support system (living alone or with partner, marital status, family care giver), 
domestic services (home help and care) and the way of living (self-reliant or community 
dwelling, assisted living or nursing home). Assessments were classified within the frailty 
domain when they were used as frailty index or instrument (for instance, Fried Frailty 
Phenotype, Rockwood Frailty Index, Groningen Frailty Indicator), which assessed the 
frailty status.
statistical analysis
Measures of central tendency of continuous variables from the trials were recorded 
as mean with standard deviation (SD) or median with interquartile range (IQR). For 
dichotomous variables the number of subjects with the characteristic divided by the 
total number of subjects was recorded. We plotted the proportion of trials in which 
either geriatric assessment was reported in the population descriptives or in the in- and 
exclusion criteria. As a sensitivity analyses we used different cut-offs for the definition of 
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“specifically designed for older patients” using a minimum mean age of 70 years or 80 
years instead of 60 years in the main analysis. All analyses were performed with IBM SPSS 
Statistics version 23.0.
ResulTs
The analysis in the present review started with 1369 articles. Of these 1369 articles, some 
articles described more than one RCT (adding a total of 24 RCTs), articles were further 
excluded because there was no RCT design after second review (n= 11) or no full-text 
was available (n= 1). After all the articles with a mean age <60 years or the articles were 
no mean age was available were removed. We ended up with 300 articles specifically 
designed for older people included for this analysis. (Fig 1) A full database of all 300 in-
cluded publications, including authors, titles and journal of publication can be assessed 
(S1 Appendix; available online).
Table 1 shows a description of the main trial characteristics of these 300 trials. The me-
dian number of participants per trial was 114 (IQR 47-288), the median of the reported 
mean age of the participants in the trials was 66 (IQR 63-70) and the median percentage 













a RCT or no full text
available (n= 12)
Articles with mean age
< 60 years (n= 975) or no 
mean age available
(n= 106)
fig 1. flow chart for inclusion of studies. PRISMA flow chart of the result from the performed search 
strategy and selection process. 
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of men included in the trials is 60 (IQR 45-72). Most of the trials were classified into WHO 
disease categories circulatory (25%), neoplasms (19%), musculoskeletal (9%), nervous 
(8%) and digestive (6%).
Fig 2 shows the proportion of RCTs that reported on geriatric assessments in the patient 
characteristics. In 102 trials (34%) somatic status, physical and mental functioning, social 
environment or frailty were reported in the patient characteristics. In 73 trials (24%) 
these geriatric domains were reported in the in-, or exclusion criteria , and in 83 trials 
(28%) geriatric domains were reported in the population descriptives. In total of the 300 
trials somatic status was reported 23 times (8%), physical functioning 67 times (22%), 
mental functioning 41 times (14%), social environment 20 times (7%) and frailty was 
only reported 2 times (1%). (Fig 3)
When selecting trials with a reported mean age of 70 years and older (n=78), 46% of 
the trials report geriatric assessments in the patient characteristics. When selecting tri-
als with a reported mean age of 80 years and older (n=13), 85% of all trials report on 
geriatric assessments in the patients characteristics (Fig 2).
Table 1. Main trial characteristics of the 300 included RCTs
Main trial characteristics n= 300
Number of participants, N
(median, IQRa)
114  (47-288)
Age of participants, years
(median, IQR)
66  (63-70)
Percentage men included in trial
(median, IQR) b
60  (45-72)
Disease categories, N (%)
Circulatory 74   (25)
Neoplasms 56   (19)
Musculoskeletal 28   (9)
Nervous 23   (8)
Digestive 19   (6)
Other 100 (33)
aInterquartile range, difference between 25th and 75th percentile is reported























































































































The main fi nding of this article is that only in 34% of all trials specifi cally designed for 
older patients report of geriatric assessment in the patient characteristics.
Our results are in line with the limited evidence that geriatric characteristics are under-
reported in RCTs. Benraad et al. described that geriatric characteristics are rarely taken 
into account in RCTs on anti-depressant drugs in late-life depression [9]. There are a 
number of possible explanations of the limited report of somatic, physical and mental 
functioning, social environment and frailty in RCTs published in 2012. First, the under-
reporting of somatic, physical and mental functioning, social environment and frailty 
might suggest that they were not taken into account at all. Second, it is possible that 
assessments of somatic, physical and mental functioning, social environment and frailty 
were included in the study protocol but were not reported in the published paper. This is 
also known from literature, describing that in 12% of the trials published in high-impact 
general medical journals the exclusion criteria were not well reported [6]. Third, the in-
cluded participants in RCTs might have been implicitly selected based on protocol level, 
patient level or physician level. An example of protocol level is that the study protocol 
prescribes to visit the research facility three times a week. Older patients who have an 
impaired mobility or do not have a caregiver available, will be less likely to participate 
and are implicit selected on the functional or social domain. A form of implicit selection 
on patient level is a form of healthy user bias in which only the healthy older adults 
fig 3: Proportion of RCT’s in older patients that report on diff erent geriatric assessments*. Showing 
the distribution of diff erent geriatric measurements and expressed as percentage of the total trials (n=300). 
*Some articles reporting more than one domain: 14 articles reporting two geriatric domains, eight articles 
reporting three geriatric domains and only one article reports four geriatric domains.
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are willing to participate. Implicit selection on physician level is a phenomenon also 
described in literature, in which eighteen percent of the treating physicians stated that 
they had not off ered their older patients a clinical trial because of comorbid conditions 
that might have aff ected their response to treatment, even though they had met the 
eligibility criteria for the trial [10]. In conclusion, as a result of the very limited report of 
somatic, physical and mental functioning, social environment and frailty, the external 
validity of the trial results is very limited. This might hamper the extrapolation of the 
trial results to individual older patients who suff er from functional impairment or frailty.
Literature describes that assessment of external validity is complex [11] but at least the 
characteristics of the included study population should be described in a transparent 
fashion [12] and therefore at least include patient and disease characteristics [13]. The 
included study population can be assessed by the description of the in- and exclusion 
criteria and patient and disease characteristics are usually found in the population 
descriptives. Especially in case of older adults, because of their huge heterogeneity as 
described previously, it is important to have a complete insight of the patient character-
istics. We realise that insuffi  cient time or funding can be one of the reasons not taking 
the geriatric assessment into account. However, this step has to be taken to gain better 
insight whether the results are applicable to older adults seen in regular practice [14, 
15]. The choice of the domain assessed and instruments used depends on the patient 
population, the intervention and the outcome, unfortunately literature has no consensus 
on this point yet. From the present review we can conclude that it is currently diffi  cult for 
the clinician to judge for which older adult the results of RCTs can be applied. This adds 
to the lack of evidence that already exists because of the very limited number of trials 
that specifi cally targets older patients.
We included only RCT’s with a median age of 60 years or older. It is not expected that 
trials including younger adults perform geriatric assessments. Although the age of 60 
years and older is chosen rather arbitrarily, it is striking that even in this sub-selection 
only one third of the trials reports on geriatric assessments to describe its population. 
Even when selecting the RCTs with a median age of 70 and older, not even half of the 
trials reporting on geriatric assessments. Only when selecting RCTs with a median age of 
80 and older, the report on geriatric assessments 85%, however this is just representing 
less than one percent of all the included trials.
There are a few limitations to this systematic review. Our search was limited to a 10% 
random sample of the identifi ed publications from 2012. However, since it contains a 
random sample, we can assume this is a representative sample, although we did not 
formally test this. Second, we excluded 106 articles in were no mean age was reported. 
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The main strength of this review is that it is was currently not known how somatic status, 
physical and mental functioning, social environment and frailty are used and reported 
in RCTs. This review gains more insight in the external validity of RCTs for older adults.
Conclusion
Somatic status, physical and mental functioning, social environment and frailty are 
underreported even in RCTs specifically designed for older patients published in 2012. 
Therefore, it is unclear for clinicians to which older patients the results can be applied. 
We recommend systematic to transparently report these relevant characteristics of 
older participants included in RCTs.
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3 HEALTH OUTCOMES IN OLDER PATIENTS WITH 
HEAD AND NECK CANCER, A SYSTEMATIC REVIEW
30 Chapter 3
absTRaCT
objectives Older head and neck cancer patients are at increased risk for adverse health 
outcomes, but little is known about which geriatric assessment associates with poor 
outcome. The aim is to study the association of functional or cognitive impairment, 
social environment and frailty with adverse health outcomes in patients with head and 
neck cancer.
Methods Four libraries were searched for studies reporting on an association of func-
tional or cognitive impairment, social environment and frailty with adverse outcomes in 
head and neck cancer patients.
Results Of 4158 identified citations, 31 articles were included. The mean age was ≥60 
years in twelve studies (39%). Geriatric conditions were prevalent: between 40-50% of 
the included participants were functional impaired, around 50% had depressive symp-
toms, and around 40% did not have a partner. Functional impairment was assessed in 
18 studies, two studies reported on a cognitive test, eight studies examined mood and 
social status was depicted by 14 studies. None of the included studies addressed frailty 
or objectively measured physical capacity such as hand grip strength, gait speed or 
balance tests. In 64% of the reported associations, a decline in functional or cognitive 
impairment, mood or social environment was associated with adverse outcomes.
Conclusion Functional and cognitive impairment, depressive symptoms and social 
isolation are highly prevalent in head and neck cancer patients and associate with high 
risk of adverse health outcomes. In the future, these measurements may guide decision-
making and customize treatments, but more research is needed to further improve and 




With population ageing there will be an increasing number of older patients with can-
cer. This trend can also be observed in the patient population presenting with head and 
neck cancer. In the USA, it is estimated that between 2010 and 2030 the incidence of 
oral cavity and pharyngeal cancer in people aged 65 years and over will approximately 
increase from 19.000 patients in 2010 to 31.000 patients in 2030. This would be an 
increase with more than 60% [1]. Older patients are very heterogenic with respect to 
functional capacity, cognitive functioning, mobility and frailty, therefore it remains chal-
lenging to identify older patients who are at highest risk for adverse health outcomes 
such as delirium, side-effects, prolonged length of hospital stay, reduced quality of life 
or mortality. Besides, head and neck cancer patients have a severe prognosis with an 
estimation of 50% after 5 years with large variations across tumor sites [2, 3]. However, 
the prognostic value of functional capacity, cognitive functioning, mobility and frailty 
to assist clinical decision making in older head and neck cancer patients has not been 
systematically evaluated.
Head and neck cancer patients have a high prevalence of previous excessive alcohol 
drinking and smoking [4-6] putting this group at high risk for deterioration in functional 
[7] and cognitive decline [6, 8]. Previously identified risk predictors in older patients with 
head and neck cancer are the burden of comorbidities [9] and nutritional status [10, 
11]. A recent review concluded that there was strong evidence for a positive association 
of pre-treatment physical functioning with survival and change in global quality of life 
[12]. But, with regard to other HRQoL domains (emotional, cognitive and social function-
ing) there was insufficient evidence. In other fields of geriatric medicine the value of 
measures of functional capacity, cognitive functioning, the role of social environment 
and frailty [13-15], has been firmly established, but these have not been reviewed for 
older patients with head and neck cancer.
Therefore, the aim of this present systematic review is to study the association of 
functional or cognitive impairment, social environment and frailty with adverse health 




We aimed to identify original longitudinal studies in head and neck cancer patients in 
which the association between a measurement of functional and cognitive impairment, 
social environment or frailty prior to treatment initiation and adverse health outcome 
after follow-up was examined. A head and neck tumour was defined as cancers in the 
sinonasal, nasopharyngeal, oral, oropharyngeal, hypopharyngeal, supraglottic, glottis, 
subglottic regions or laryngeal cancer. Since the etiologic, risk factors and treatment for 
skin tumors and thyroid cancer are different from mucosal tumors, skin tumors and thy-
roid cancers were not included in the search. As baseline measurement we assessed the 
presence of functional impairment (including assessment of functional performance, 
mobility, and objectively measured physical capacity such as hand grip strength, gait 
speed or balance tests), cognitive impairment (including assessment of cognition, de-
mentia diagnosis, and mood or depression), social environment (living situation, social 
support and marital status) and frailty (the use of a frailty index or instrument such as 
Fried Frailty Phenotype or the Groningen Frailty Indicator). We assessed adverse health 
outcomes as mortality, functional or cognitive decline, adverse events during or after 
treatment (such as side-effects or delirium), prolonged length of hospital stay (LOS) and 
health related quality of life (HRQoL) of global quality of life (QoL) after follow-up.
On April 28th 2016, we searched four electronic bibliographic databases (PubMed, 
Embase, Web of Science and the Cochrane Library) using synonyms of head and neck 
cancer, combined with synonyms of the different domains of geriatric assessment. No 
limits in age were applied. For full Medline search, see Supplemental Material A (avail-
able online).
article selection
The eligibility of all studies identified by the search was independently evaluated by 
two of the authors (F.v.D and A.S). Of any article that seemed potentially relevant based 
on title and abstract, full text was retrieved and screened. Studies were included if the 
full text contained original data reporting on an association between any geriatric 
measure at baseline and outcome after follow-up in head and neck cancer patients in 
a longitudinal study design. In case of disagreement between the two authors (F.v.D., 
A.S.), consensus was reached after discussion with two other co-authors (S.P.M., L.vd.V.). 
The reference list of the included publications was used for cross-referencing to ensure 
we identified all relevant articles.
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Data extraction and quality assessment
Items extracted from each study included: publication data (author, year), study design 
and setting, patient characteristics (sample size, mean age, treatment modality), tumor 
type and tumor site measurement of functional or cognitive impairment, social envi-
ronment or frailty, follow up duration, outcome measure and results of the association 
functional and cognitive impairment, social environment and frailty with adverse health 
outcome. Treatment modality can include therapy with a curative intent such as surgery, 
radiation therapy, chemoradiation (or as a combination) or with no curative intent such 
as chemotherapy, and also no treatment with palliative intent was taken into account 
as a treatment modality. To assess the methodological quality and risk of bias of the 
included studies, we adapted the Newcastle-Ottawa scale [16] to the purpose of this 
review (Supplemental Material B, available online). In case of disagreement between the 
two authors (F.v.D., A.S) with regards to data extraction or quality assessment, consensus 
was reached after discussion with the other two co-authors (S.P.M., L.vd.V.).
Data presentation
Study characteristics are tabulated per individual study. Accumulated descriptives of 
the selected studies are presented by calculating the proportion of studies reporting 
on measurement of functional or cognitive impairment, social environment or frailty, 
endpoints or treatment modalities. Sample size aggregate of the included studies is 
expressed as median- and interquartile range (IQR), calculated with SPSS software ver-
sion 20. Main findings with respect to the association of measurement of functional or 
cognitive impairment, social environment or frailty with outcome are tabulated. In case 
the hazard ratios (HR), odds ratios (OR) and relative risk (RR) are at least adjusted for age 
in the multivariate analysis this is mentioned as aHR, aOR and aRR. If studies are adjusted 
for other factors than age, this is reported in the abbreviations.
ResulTs
search results and study selection
The database searches identified 4158 unique citations (Figure 1). After the initial 
screening of title and abstract, 106 articles were considered potentially eligible. After 
full-text review, another 76 were excluded; the remaining 30 articles were included. 
Cross referencing yielded one additional relevant article, which resulted in a total of 31 
studies that were included in the present review.
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study characteristics
Table 1 shows an overview of the study characteristics of the 31 included studies. The 
median sample size of all 31 studies included was 306 (IQR 124-600) and the mean age 
was over 60 years in twelve studies (39%). Twenty-one studies (68%) were conducted in 
Europe, the United States or Canada. Most studies consisted of head and neck cancer 
patients with various cancer types and locations combined, six studies included patients 
with a specific kind of tumor, five studies had specific inclusion criteria such as stage III/
IV or (locally) advanced cancer and six studies included only one treatment modality. 
Only three studies focused exclusively on older patients and included age ≥70 years 
in their study population [17-19]. Several studies used specific exclusion criteria: four 
excluded patients with cognitive impairment, five excluded specific cut off for age, such 
as excluding aged over 70, 75 or 80 years, some functional impairment (n=3) or patients 
with no curative intent (n=8).
All studies n= 8120
Pubmed                  n= 3241
Embase n= 3076
Cochrane n= 397
Web of science n= 1406
Citations screened n= 4158
Included n= 30
Cross referencing n= 1
Final inclusion n= 31
Duplicates n= 3962
Exclusion (total) n= 4128
Animal study n= 46
Not in English n= 443
Not original research n= 599
Not the selected population n= 570
No longitudinal design n= 210
No geriatric assessment n= 1922
No relevant outcome n= 338


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2 shows an overview of the associations of measures of functional or cognitive 
impairment, social environment and frailty with adverse health outcomes after follow 
up. The thirty-one studies reported on a total of 45 associations. Functional impairment 
was assessed in 18 studies, there were two studies reporting on a cognitive test, eight 
studies examined depressive symptoms and social status was studied in 14 studies. 
None of the studies addressed frailty or objectively measured physical capacity (such as 
hand grip strength, gait speed or balance tests). Survival (overall, total or disease specific 
survival) was the main outcome of interest in 21 studies (68%), the remaining studies as-
sessed quality of life (global or health related, 19%), side effects (7%), the development 
of post-treatment delirium (7%) or prolonged length of stay in the hospital (7%). No 
studies were found reporting on cognitive or functional decline after treatment for head 
and neck cancer. Of the 45 reported associations, twenty-nine times (64%) a decline in 
functional or cognitive performance, mood or social environment was associated with 
an increased risk of one of the adverse outcomes (Figure 2).
Functional impairment
Functional performance was assessed in 18 studies, mostly using the Eastern Coopera-
tive Oncology Group Scale (ECOG-scale, 6 studies)[19-24], or the Karnofsky Performance 
Score (KPS, 8 studies)[17, 18, 25-30]. Functional impairment was prevalent in most 
studies. For instance, the largest study of Siddiqui et al, included 1093 patients and 517 
(47%) had a KPS between 60 and 80, indicating patients were not able to work or need 
some help with daily care. Functional impairment was associated with increased risk of 























































Figure 2: Graphic representation of association of functional or cognitive impairment and social 
environment with adverse health outcomes in patients with head and neck cancer.  
No studies reported the association between frailty and adverse health outcomes.  
 
figure 2: Graphic representation of association of functional or cognitive impairment and social environ-
ment with adverse health outcomes in patients with head and neck cancer. 
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be associated with (overall) survival in 9 out of 12 studies (75%) [18, 20, 21, 23, 25, 27, 29-
31]. Siddiqui et al and found that KPS (90-100 vs 60-80) was an independent prognostic 
factor for overall survival (aHR 1.51 (95% CI 1.27-1.79)).
Cognitive impairment
There were only two articles that reported on the association between cognitive status 
and adverse health outcome. Shah et al reported a prevalence of cognitive impairment 
of 5%, defining pre-existing cognitive impairment as any history or physical findings 
of stroke, transient ischemic attack or dementia [32]. The outcome measured was the 
development of a postoperative delirium, and 11 out of 39 patients with cognitive im-
pairment developed a postoperative delirium (28%). Pre-existing cognitive impairment 
was significant correlated with a postoperative delirium (aHR 3.83 (95% CI 1.70-8.63)). 
Weed et al measured cognitive function using the Folstein Mini-Mental State question-
naire (MMS) [33]. In this study 24 out of 138 patients (17%) developed a postoperative 
delirium, and these 24 patients had a mean MMS-score of 26.3 [34]. In this small sample 
size, there was no association reported of cognitive status measured by the the Folstein 
Mini-Mental State questionnaire with the development of postoperative delirium.
Eight studies examined depression by using five different types of inventories using 
different scales. The study of Ronis et al, assessed depression by using the GDS-SF and 
156 of 316 patients (49%) had significant depressive symptoms at baseline, and about 
the same prevalence was found in other studies. Five out of eight studies (62.5%) found 
a significant association of depression with an increased risk of one of the adverse health 
outcomes. In four studies assessing depressive symptoms was found that depressive 
symptoms at baseline were associated with lower global/health related quality of life 
after follow-up [35-38]. Depressive symptoms at baseline were a significant predictor 
of a negative change in HRQoL one year after diagnosis (adjusted for age p=<0.05, no 
estimation reported). The association of mood/depression and survival as outcome is 
inconsistent. One study [39] found that depression, measured by Beck Depression In-
ventory (BDI), at baseline predicts overall survival (aHR 1.13; p=0.03) and disease specific 
survival (aHR 1.19; p<0.001). On the other hand Karvonen et al measured depression by 
the Geriatric Depression Scale Short Form (GDS-SF) and found that this was no signifi-
cant prognostic factor for overall survival (HR 1.30 (95% CI 0.98-1.73))[40] and also Kim 
et al found that pre-treatment depression was not significant predictive for three-year 
overall survival (aHR 1.52 (95% CI 0.82-281))[41].
Social environment
Fourteen studies examined social environment and this was mostly assessed by marital 
status (34%) and living situation (10%), one study used Social Provision Scale (SPS). 
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Around 35% of the participants did not have a (married) partner. Ten out of fourteen 
studies (71%) found an association of social environment with one of the outcomes. Six 
studies found that marital status (not married or not having a partner) was associated 
with a worse overall survival [26, 30, 40, 42-44] and two studies did not find an associa-
tion [25, 45]. The quality of life after 3, 6 or 12 months was lower in patients who did not 
have a partner compared to patients who did have a partner [46, 47]. There was only one 
study assessing the living situation with overall survival, this study found that patients 
living dependently had a higher risk for a reduced overall survival (aRR 2.33, p=<0.001) 
and disease specific survival (aRR2.16, p=<0.001) [48].
Quality assessment
The overall study quality assessed by the modified Newcastle-Ottowa scale was moder-
ate (Table 3). Overall there were some concerns regarding the validity of the selection, 
the determination of outcome or reporting of the duration of follow up. The greatest 
concern with a majority of the studies was the representativeness of the study popu-
lation, as 14 studies (48%) examined the association between a geriatric measure at 
baseline with outcome in a selected population in which only one kind of tumor, one 
kind of treatment modality or treatment intent was used. Furthermore, in several studies 
a risk of selection bias persisted because of various reasons: excluding older patients, 
cognitive impaired patients or with a restriction on the functional performance [17, 26, 
27, 30, 35, 37, 39, 41, 42, 45, 46].
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DIsCussIon
In the present systematic review, we identified 31 articles reporting on the association of 
functional or cognitive impairment, social environment or frailty with adverse outcomes 
in patients with head- and neck cancer. There were three main findings: first, the decline 
in functional performance, depressive symptoms and decline in social environment 
were prevalent. Second, the majority of the studies reported a statistically significant 
association of impairment in functional and cognitive performance, mood or social 
environment with a higher risk of adverse outcome. Third, cognitive function was only 
assessed in two studies and frailty and objectively measured physical capacity, were not 
assessed at all in patients with head and neck cancer.
Impairment in functional performance, depression and social environment were 
highly prevalent, which emphasizes that the head and neck cancer patients are a very 
vulnerable patient group. Possibly, the observed associations in the present review are 
underestimated due to the relatively young population in the studies compared to the 
average population in the clinic, with only twelve studies (39%) reaching a mean age of 






















Kim 2015 + + + +/- +
Konski 2003 +/- + + ? ?
lotfi 2008 + + + + +
Mell 2010 +/- + + + ?
oskam 2010 +/- + + + ?
osthus 2013 + + + + +
Pedruzzi 2008 +/- + + + ?
Ronis 2008 + + + + + 
sadat 2012 - + + + ?
sanabria 2007 + + + + ?
shah 2012 +/- + + ? ?
siddiqui 2008 +/- + + + ?
sze 2012 +/- + + + ?
Tarsitano 2012 - + + + ?
urba 2012 +/- + + +/- + 
Wang 2014 + + + + ? 
Weed 1995 +/- + + ? ?
Wong 2006 +/- + + + ?
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60 years and older. According to the Surveillance, Epidemiology, and End Results data-
base, approximately 47% of all patients diagnosed with head and neck cancer (HNC) in 
the U.S. between 1973 and 2013 were 65 years and older [49]. It is not surprising that we 
find limited number of older patients in these studies. A review in 2012 showed that only 
7% of all randomized clinical trials are specially designed for older adults [50]. It is also 
known over various fields in medicine that older patients are underrepresented in clini-
cal studies as a result of excluding individuals over a certain age or with a high burden 
of morbidities [50, 51]. As a consequence, subjects enrolled in clinical trials, even those 
in the oldest cohort, often do not represent older patients in the general population 
[52, 53]. Based on the results of the studies included in our review, we cannot determine 
which individual patient would experience adverse health outcomes and therefore 
the external validity of the individual studies is limited. The limited external validity 
is caused by the heterogeneous population, investigating a wide range of head and 
neck cancer types and treatment modalities and regimes, inclusion criteria, number of 
included patients, used geriatric assessment, age groups and outcome measurements.
Despite the heterogeneity of the studies and the low numbers of studies studying 
older patients it is the majority of included studies reported a significant association 
of functional impairment and social environment and some on cognitive impairment 
with adverse outcomes. These associations also have been shown in other oncology 
patients [54-56] and in community dwelling older people [14, 57]. In general oncology, 
geriatric assessments are frequently used to guide treatment decision-making. General 
oncologists often assess functional capacity by assigning KPS and ECOG-score, and both 
assessments are independent prognostic factors for outcomes [58, 59]. In (oncological) 
surgery cognitive impairment is a well-known risk factor for postoperative complications 
such as delirium and mortality [60-62]. In two recent meta-analyses depression diagno-
sis and higher levels of depressive symptoms in patients with different kind of cancers 
predicted elevated mortality [63, 64]. Social isolation has been linked to an increased 
risk of mortality in geriatric and oncology literature [65, 66]. This could be explained 
by the intensive treatment program for (head and neck) cancer, the chances of success 
of the intensive treatment is highest when there is a good social support. Although 
we cannot rule out publication bias with negative associations not being published, 
our findings are in line with the literature describing associations of impairments with 
adverse outcome. Most of the studies identified in the present systematic review, found 
an association with social status, depicted by marital status, and a worse overall survival.
Multiple promising geriatric assessments, such as various frailty indices and objectively 
measured physical capacity were not assessed in patients with head and neck cancer. 
Objective geriatric measurements, such as gait speed, handgrip strength or Timed 
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Up to GO Test (TUGT) can be useful geriatric screenings tools for the physician to risk 
stratify patients. Several studies examining the relation between physical capacity and 
outcomes as mortality or disability, found an association both in general and in onco-
logical patient populations [67-70]. Frailty is associated with adverse health outcomes 
in surgical patients [61] as well in community dwelling older adults [14]. In addition, in 
a recent review in older cancer patients, frailty is associated with an increased risk of 
chemotherapy intolerance, postoperative complications and mortality [71]. In conclu-
sion, both objective geriatric measurements and frailty are predictive of poor outcomes 
in general oncology, (oncologic) surgical patients, as well as community dwelling older 
adults. However, in older head and neck cancer patients evidence of physical capacity 
and frailty and its associations with adverse health outcomes is lacking.
A limitation of our study was that, due to heterogeneity among the included studies, 
especially with respect to the geriatric measure that was used, the reported measure of 
association (HR, OR, and relative risk), outcome measures, and covariate adjustments, 
made it impossible to compare outcomes of studies in a meta-analysis or to make a 
proper sub group analysis. Secondly, interpretation of the results may be hampered by 
possible publication bias, as negative associations in multivariate analyses may not have 
been reported in the studies. Strengths of this review include the systematic search we 
performed in several databases, assessing all potential relevant associations of functional 
and cognitive impairment, social environment and frailty with adverse health outcomes 
in head and neck cancer patients. Furthermore, quality assessment of the studies was 
undertaken to identify potential factors hampering external validity.
Our findings implicate that apart from specialists in head and neck oncology (such as 
head and neck surgeons and oncologists) the older head and neck cancer patient could 
benefit from an even more multidisciplinary approach. This could be implemented for 
instance by including a geriatrician in the multidisciplinary team in both the pre- and 
post-operative phase.
Conclusion
Functional and cognitive impairment, depressive symptoms and social isolation are 
highly prevalent in head and neck cancer patients and associate with high risk of ad-
verse health outcomes. In the future, these measurements may guide decision-making 
and customize treatments, but more research is needed to further improve and firmly 
establish clinical usability.
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background Older patients with esophageal cancer are at high risk of adverse health 
outcomes, but the association of geriatric assessment with adverse health outcomes in 
these patients has not been systematically evaluated. The aim of this systematic review 
was to study the association of functional and cognitive impairment, social environment 
and frailty with adverse health outcomes in patients diagnosed with esophageal cancer.
Methods We searched Pubmed, Embase, Web of Science and Cochrane Library for 
original studies reporting on associations of functional or cognitive impairment, social 
environment and frailty with adverse outcomes (mortality, functional or cognitive de-
cline, adverse events during treatment, prolonged length of hospitalization (LOS) and 
health related quality of life (HRQoL)) after follow-up in patients with esophageal cancer.
Results Of 1.391 identified citations, nineteen articles were included that reported on 
53 associations. The median sample size of the included studies was 110 interquartile 
range (IQR 91-359). Geriatric conditions were prevalent: between 14 and 67% of the in-
cluded participants were functionally impaired, around 42% had depressive symptoms 
and between 5 and 23% did not have a partner. In nineteen of 53 (36%) associations 
functional or cognitive impairment or frailty were significant associated with adverse 
health outcomes, but the studies were small. In four out of six (67%) associations with 
the largest sample size (n≥359), functional impairment or social environment were 
significant associated with adverse health outcomes.
Conclusion Functional and cognitive impairment, depression and social isolation are 
prevalent in patients with esophageal cancer, and associate with adverse health out-
comes. Geriatric measurements may guide decision-making and customize treatments, 




Esophageal cancer incidence strongly increases with age. In 2016 in the Netherlands 
there were 2545 newly diagnosed patients with esophageal cancer and in > 65% of these 
diagnoses the patient was 65 years of older [1]. Also the UK and the USA report similar 
numbers [2]. Esophageal cancer is associated with a poor prognosis, having an overall 
five-year survival ranging between 15 and 20% depending on the stage and treatment 
intention [3]. It is a challenge to select the older patients who are at high risk for adverse 
health outcomes, such as mortality, prolonged length of stay and reduced quality of life. 
This is mostly due to their varying levels of functional and cognitive capacity, mobility 
and frailty. However, it is unclear how geriatric impairments, such as functional and 
cognitive impairment or frailty, associate with adverse outcomes in patients diagnosed 
with esophageal cancer.
The optimal treatment for locally advanced esophageal cancer consists of preoperative 
concomitant chemoradiotherapy followed by surgical resection [4, 5] and the optimal 
treatment for early stage esophageal cancer is surgical or endoscopic resection [6]. 
In patients aged 70 years and older, esophagectomy has been associated with higher 
mortality and morbidity rates compared to patients younger than 70 years [7-10]. Often 
there is reluctance to have older patients undergo the general treatment modalities [11], 
because of their comorbidities, polypharmacy or poor physical functioning [12]. In other 
fields of medicine, recent research has shown that performing a geriatric assessment 
including the domains of functional or cognitive functioning, social functioning and 
frailty may guide decision making for older patients undergoing general surgery [13].
The aim of this systematic review was to study the association of functional and cognitive 
impairment, social environment and frailty prior to any treatment with adverse health 
outcomes (mortality, functional or cognitive decline, adverse events during treatment, 
prolonged length of hospitalization (LOS) and health related quality of life (HRQoL) after 




We aimed to identify original longitudinal studies in patients with esophageal cancer 
with all disease stages, in which the association between a measurement of functional 
and cognitive impairment, social environment or frailty prior to any treatment initiation 
and adverse health outcome (mortality, functional or cognitive decline, adverse events 
during treatment, LOS and health related quality of life (HRQoL) after follow-up) after 
follow-up was examined.
One of the purposes of a geriatric assessment is to systematically explore different 
domains (functional status, cognitive status, social environment and frailty) as a reflec-
tion of patients’ health [14, 15]. Therefore, using the geriatric assessment at baseline 
we determined functional capacity (including assessment of functional performance, 
mobility, and objectively measured physical capacity such as hand grip strength, gait 
speed or balance tests), cognitive capacity (including assessment of cognition, dementia 
diagnosis, and mood or depression), social environment (living situation, social support 
and marital status) and frailty (as measured using a frailty index or instrument such as 
Fried Frailty Phenotype or the Groningen Frailty Indicator). The geriatric assessment had 
to be done before treatment initiation. In this review articles describing patients treated 
with any of the available treatments are eligible (surgery, chemotherapy, (chemo)radio-
therapy, palliative supportive care). We expect that a geriatric assessment mostly will 
be performed in older patients, though they might be relevant to younger patients as 
well. To decrease the risk of missing relevant articles we did not apply age limits in the 
search strategy. An esophageal tumor was defined as squamous cell carcinoma (SCC) or 
adenocarcinoma carcinoma (AC) of the esophageal wall or gastro-esophageal junction, 
all disease severity stages were included. Adverse health outcomes were defined as 
mortality, functional or cognitive decline, adverse events during treatment (e.g. delirium 
or side-effects), prolonged length of hospitalization (LOS) and health related quality of 
life (HRQoL) or global quality of life (QoL) after follow-up.
On December 19th 2016, we searched four electronic bibliographic databases (PubMed, 
Embase, Web of Science and the Cochrane Library) using synonyms of esophageal can-
cer, combined with synonyms of the different domains of geriatric assessment. For the 
full Medline search, see Appendix A (available online).
article selection
The eligibility of all studies identified by the search was independently evaluated by 
two authors Floor van Deudekom (FvD) and Henk Klop (HK). Of any article that seemed 
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potentially relevant based on title and abstract, full text was retrieved and screened. 
Studies were included if the full text contained original data reporting on the associa-
tion between any of the geriatric measures at baseline and outcome after follow-up in 
patients with esophageal cancer in a longitudinal study design. In case of disagreement 
between the two authors (HK, FvD), consensus was reached after discussion with two 
other co-authors (MS and SM). In 1372 of the 1391 articles HK and FvD had consensus, 
making a 98% agreement overall. The reference list of the included publications was 
used for cross-referencing to ensure we identified all relevant articles.
Data extraction
Data extracted from each study included: publication data (author, year), study design 
and setting, patient characteristics (sample size, mean age, treatment modality), tumor 
type (SCC or AC) measurement of functional or cognitive impairment, social environment 
or frailty, follow up duration, outcome measures and results of the association functional 
and cognitive impairment, social environment and frailty with adverse health outcome. 
Treatment modality can include therapy with a curative intent such as endoscopic 
resection, surgery, surgery in combination with neoadjuvant chemoradiation, chemo-
radiation alone or treatment with no curative intent such as palliative chemotherapy or 
palliative radiotherapy or esophageal stent placement. Also, best supportive care was 
considered as a treatment modality. To assess the methodological quality and risk of bias 
of the included studies, we adapted the Newcastle-Ottawa scale [16] for the purpose 
of this review (Appendix B). The Preferred Reporting Items for Systematic Reviews and 
Meta-analyses (PRISMA) checklist, which is a checklist for evidence-based minimum set 
of items for reporting in systematic reviews [17], is available (online) see Appendix C.
Data presentation
Study characteristics are tabulated per individual study. Accumulated descriptive sta-
tistics of the selected studies are presented by calculating the proportion of studies re-
porting on measurements of functional or cognitive impairment, social environment or 
frailty, endpoints or treatment modalities. Combined sample size of the included studies 
is expressed as median and interquartile range (IQR). To get a complete overview we 
describe the total of significant associations with outcomes. All calculations are made 
with Statistical Package for the Social Sciences (SPSS) software version 23. In this review 
with an “association” is meant the relation between the geriatric determinant at baseline 
and the outcome after follow up. Main findings of the studies with respect to the as-
sociation of measurement of functional or cognitive impairment, social environment 
or frailty with outcome are tabulated. If possible, a fully adjusted model controlling for 
possible confounders, including multiple known risk factors for poor outcome, such as 
comorbidity burden, was tabulated.
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Supplementary analysis
Because of a low average sample size in the found articles, which can result in low power 
to detect statistical significance, we performed a supplementary analysis. In this analysis 
we analyzed the five studies with the largest sample size and describe the association of 
measurement of functional or cognitive impairment, social environment or frailty with 
the outcome of interest.
ResulTs
search results and study selection
The database searches identified 1391 unique citations (Figure 1). After screening of title 
and abstract, 66 articles were considered potentially eligible. After full-text review, 47 
were excluded; the remaining nineteen articles were included. Cross-referencing did not 
result in additional articles, so a total of nineteen articles were included in this review.
All studies n= 2489
Pubmed                  n= 1031
Embase n= 997
Cochrane n= 89
Web of science n= 372
Citations screened n= 1391
Full text screened n= 66
Final inclusion n= 19
Duplicates n= 1098
Exclusion (total) n= 1306
Not in English n= 109
Animal or cell line study n= 46
Not original research n= 305
Not the selected population n= 182
No longitudinal design n= 68
No geriatric assessment n= 533
No relevant outcome n= 11
Association between geriatric assessment                  n= 56
and outcome not assessed
Exclusion (total) n= 47
Not the selected population n= 5
No geriatric assessment n= 22
No relevant outcome n= 3
Association between geriatric assessment                 n= 17





Table 1 shows an overview of the study characteristics of the nineteen included stud-
ies. Eighteen out of nineteen studies (95%) were published after the year 2000. The 
median sample size of the included studies was one hundred ten (interquartile range 
(IQR) 91-359). Ten out of nineteen studies (53%) were conducted in the United States or 
Europe. Out of the nineteen studies, thirteen studies (68%) included adenocarcinoma 
and squamous cell carcinoma; six studies (32%) included patients with only one of 
those two types. Four studies had specific selection criteria such as (locally) advanced 
cancer, ability to complete self-report questionnaires and seven studies included only 
one treatment modality. Only two studies (11%) focused on older patients and included 
exclusively patients aged 70 years and older in their study population.
association of measures for functional status, cognitive or social functioning 
with adverse health outcomes
Table 2 shows an overview of the associations of measures of functional or cognitive 
impairment, social environment and frailty with adverse health outcomes after follow up. 
The nineteen studies reported on a total of 53 associations between various determinants 
with adverse outcomes: 25 out of 53 associations (47%) assessed functional impairment, 
ten out of 53 associations (19%) were reporting on cognitive function, two out of 53 as-
sociations (4%) examined depressive symptoms, social status was studied in eleven out 
of 53% associations (21%) and physical capacity was studied in five out of 53 associations 
(9%) (Figure 2). Objectively measured physical capacity, such as hand grip strength or the 
six-minute walking test was examined in five associations (9%). None of the studies used 
an instrument to measure frailty as a determinant of adverse health outcomes.





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Survival (overall, total or disease specific survival) was the main outcome of interest in 26 
out of 53 associations (49%). From the remaining associations seventeen assessed side 
effects (32%), QoL or HRQoL was assessed by one association (2%), four assessed the de-
velopment of post-treatment delirium (7.5%), one assessed depressive symptoms (2%), 
three assessed early recurrence (5.5%) and one assessed LOS (2%). No studies reported 
on cognitive or functional decline after treatment for esophageal cancer.
In nineteen out of 53 associations (36%) in all included studies and in four out of six 
(67%) of the studies with the largest sample size, functional, cognitive or social func-
tional impairment was statistically significantly associated with a higher risk of adverse 
health outcomes.
Functional impairment and physical impairment
Nine of the associations reporting on overall functional performance used the European 
Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire 
(QLQ)-C30 [18-23], four used the Karnofsky Performance Score (KPS) [18, 21, 24, 25], six 
used the Eastern Cooperative Oncology Group (ECOG) score, three used the Zubrod per-
formance score [26, 27] and two used Barthel index and Instrumental Activities of Daily 
Living (IADL) [28]. Functional impairment was prevalent in most of the studies with rates 
between 14-67%. For example, one of the largest studies of Kawashima et al. included 
362 patients and 158 (43.6%) had a KPS<70, which indicates that patients are unable 
to carry on active work or require assistance. Functional impairment was found to be 
associated with increased risk for any adverse outcome in twelve of the 25 associations 
(47%). Kawashima et al. reported that a higher KPS (>80 versus <70) was associated with 
a higher overall survival in patients treated with definitive radiotherapy (RR 1.56 p = 
0.0009). If the data were stratified for age, the overall survival rate of 31 octogenarians 
(stage I/II) was significantly higher with increasing KPS (p = 0.009), while it did not as-
sociate with increasing survival in the 63 younger patients (p = 0.958) [25].
Two associations used inspiratory muscle strength and handgrip strength [23], while the 
other three used knee-extensor muscle strength, six-minute walking distance and Inter-
national Physical Activity Questionnaire (IPAQ) [29]. Physical impairment was associated 
with higher risk adverse outcomes in one out of the five reported associations (20%). 
The study by Tatematsu et al., included 51 participants and assessed the association 
between physical impairment and postoperative complications showing that physical 
impairment was statistically significantly associated with postoperative complications 
in multivariate analysis (odds ratio (OR) 28.3 95% confidence interval (CI) 3.5-227.7) [29].
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Cognitive impairment and depressive symptoms
Cognitive status was measured with the European Organisation for Research and Treat-
ment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30) cognitive scale, 
which contains one self-report question on cognitive performance, in nine out of the ten 
associations [18-23]. Cognitive status was found to be associated with increased risk for 
any adverse outcome in two out of ten associations (20%). The prevalence of cognitive 
impairment was not reported. Only one study by Yamamoto et al. used an objective 
assessment to measure cognition, the Mini-Mental State Examination (MMSE). In this 
study 24 of the 91 individuals developed postoperative delirium and these patients had 
a lower mean MMSE score of 23 compared to 27 in patients without delirium, indicating 
a lower cognitive status. In this study, a one point decrease in MMSE score associated 
with a 40% increased risk of delirium (odds ratio (OR) 1.4 (95% CI 1.2-1.6)) [28].
Depressive symptoms were measured with the Hospital Anxiety and Depression Scale 
(HADS) [24] and the Geriatric Depression Scale fifteen (GDS15) [28]. One study reported 
a prevalence of 42% patients having depressive symptoms. Depressive symptoms were 
associated with an increased risk for adverse outcomes in one out of two associations 
(50%). The study that assessed the association between depression and postoperative 
delirium used the GDS15. This study showed that for the 24 patients who developed a 
delirium, the mean score was 4.92 compared to a mean score of 2.45 for patients without 
delirium. A one point increase in GDS15 score, indicating a higher chance of depression, 
was associated with a 30% increased risk for delirium (odds ratio (OR) 1.3 (95% CI 1.1-
1.6)) [28]. The other study used the HADS questionnaire in 94 participants to assess if 
depressive symptoms and anxiety at baseline were associated with survival, reporting 
no significant correlations between any of the HADS scores at baseline and survival [24].
Social functioning
Social impairment was mostly measured with the EORTC QLQ-C30 social scale, in nine 
of the eleven associations [18-23]. Between 5% and 23% of the included participants 
were single and 30% lived alone. Social impairment was found to be associated with 
increased risk for any adverse outcome in three of the eleven associations (27%). A study 
by Brusselaers et al. assessed the association between social functioning, depicted by 
marital status and overall five-year mortality in 606 participants. Of these patients, 334 
were married and 272 had a different marital status (e.g. unmarried or remarried). Marital 
status was not significantly associated with five-year mortality [30].
supplementary analysis
To test the robustness of our finding that 36% of the associations reported a significant 
association of functional, cognitive or social functional impairment with a higher risk of 
adverse health outcomes, we performed a supplementary analysis.
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The average sample size in the articles is relatively low resulting in low power to detect 
statistical significance, which may explain the low number of reported significant as-
sociations. To test this hypothesis, we analyzed the five studies with the largest sample 
size [25, 27, 30-32]. This resulted in six associations, with a minimal sample size of 359 
patients. Three assessed functional status and two investigated social status, while in 
all associations survival was the main outcome. In four out of six (67%) associations a 
significant association of functional, cognitive or social functional impairment with a 
higher risk of adverse health outcomes was reported (Figure 3).
Quality assessment
The overall study quality assessed by the modified Newcastle-Ottowa scale was moder-
ate (Table 3). Overall the biggest concern was the representativeness of the study popu-
lations. In six out of the nineteen studies (31.6%), the association between a geriatric 
measure and outcome was examined in a preselected population with specific tumor 
characteristics (e.g. only locally advanced) or only one treatment modality was used. 
Furthermore, several studies had specific selection criteria, such as excluding patients 
who were cognitively impaired [21, 24, 33] or with an impaired physical status at baseline 
[29], which may increase the risk on selection bias. Finally, only in ten out of nineteen 
(53%) studies the interpretation of the results were reliable because the confounders 
and the way there was controlled for these confounders were reported.
fig. 3 Visual representation of significant associations in different selections.

















































































































































































































































































































































































































































































In the present systematic review, there were four main findings. First, geriatric impair-
ments such as functional impairment, social isolation and depressive symptoms were 
prevalent. Second, we identified nineteen articles reporting on 53 associations of func-
tional or cognitive impairment or social environment with adverse outcomes in patients 
with esophageal cancer. Third, one-third of all studies, and 67% of the studies with the 
largest sample size, reported a significant association of functional, cognitive or social 
impairment with increased risk for adverse health outcomes. Fourth, objectively mea-
sured functional and cognitive function were only assessed in one study, while frailty 
was not assessed at all in patients with esophageal cancer.
In the nineteen articles we identified, functional, physical and cognitive impairment, de-
pressive symptoms and impairment in social environment were prevalent, this confirms 
that patients with esophageal cancer are vulnerable. Major risk factors, especially for 
squamous cell carcinoma, include alcohol consumption and tobacco use. Both factors 
were also associated for deterioration in functional and cognitive decline as well [34, 
35]. Possibly, the reported prevalence in the different studies could be explained by the 
relatively young included study population, this review reports only two studies who 
exclusively included patients aged 70 years and older in their study population.
Based on the incidence of esophageal cancer in the general population [36] and based 
on experience with other reviews in head and neck patients with cancer [37] and patients 
with end-stage renal disease [38], we had expected to find more articles. The mean age 
in the included population in this systematic review was above 60 years in only eight of 
the nineteen studies (42%), while the median age of patients with esophageal cancer is 
68 years and 56% of the patients are aged 70 over at time of diagnosis [12]. It is a known 
phenomenon that clinical trials include limited numbers of older patients. This under-
representation can be explained by the exclusion of older adults because of age, comor-
bidities and polypharmacy [39] and this is also known from drug trials [40], cardiology 
trials [41, 42] and oncology trials [43]. The consequence of this underrepresentation is 
that it is unknown if the results can be applied to the individual patient in the outpatient 
department and therefore the external validity is limited. The large heterogeneity in 
inclusion criteria, treatment modalities, geriatric assessment and outcome measures, 
hampers drawing definitive conclusions for individual patients.
In this review, more than one-third of the reported associations found a significant as-
sociation of functional, cognitive or social impairment with increased risk for adverse 
health outcomes. In general oncology, oncologists often assess functional capacity by 
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assigning KPS and ECOG-score, to guide treatment decision-making. Both assessments 
are independent prognostic factors for survival [44-46]. Also, IADL has been identified as 
a significant prognostic factor for survival in lung cancer [44] and in patients with cancer 
undergoing surgery [47, 48]. In this review, one study assessed objectively assessed 
cognitive status and found an association with postoperative delirium [28]. This is in line 
with previous research that reported impaired cognitive status to be associated with 
adverse outcomes in patients undergoing thoracic surgery [49] and older patients [50]. 
In this review, social assessment by marital status, assessed in one study, was not associ-
ated with survival. In a recent systematic review in patients with head and neck cancer, 
social status depicted by marital status was associated with adverse health outcomes 
such as overall survival [37]. In general, the number of associations between functional, 
cognitive or social impairment with increased risk for adverse health outcomes was 
higher in other patients with cancer [37, 51]. One possible explanation may be the lack 
of statistical power of the included studies, as the median sample size was low (< 100 
patients). This hypothesis is supported by our finding that 67% of the associations in the 
articles with the highest sample size, associations of functional impairment or social en-
vironment with adverse health outcomes, did reach statistical significance. On the other 
hand, the number of significant associations may inversely be affected by publication 
bias, as negative associations in multivariate analyses may not have been reported in 
some of the studies. Overall, we conclude that in older patients with esophageal cancer 
impairments on functional, cognitive or social environment in 67% of the reported as-
sociations there was an increased risk of adverse outcomes.
Objectively measured functional and cognitive status were assessed in only one 
study [28]. The predictive value of a geriatric assessment, which extensively examines 
functional, physical, cognitive and social performance, has been established in other 
patients with cancer [44, 52, 53], but was not reported for patients with esophageal 
cancer. An often used concept ‘frailty’ has not been studied in patients with esophageal 
cancer. This is surprisingly since frailty is extensively described in other oncological fields 
[54-56]. Frailty also has been associated with increased risk of mortality, treatment com-
plications and treatment completion in older patients with cancer [57, 58]. However, in 
older patients with esophageal cancer evidence of physical capacity and frailty and its 
associations with adverse health outcomes is lacking.
A limitation of the present review is that we did not perform a meta-analysis. Due to 
the heterogeneity of the included studies with respect to the low number of included 
patients, geriatric measures that were used, outcome measures and the reported as-
sociation measure (HR, OR and RR) and often the absence of an estimate of the effect, 
a summary statistic would be hard to interpret. A cumulative statistic of associations 
4
71
would only provide information to the reader about whether an overall association ex-
ists in a statistical way. Clinical usefulness of such a summary statistic would be minimal 
as it is unclear what determinant associates with what outcome and whether or not 
there is confounding or bias. Strengths of this review include the systematic search 
we performed, assessing all potential relevant associations of functional and cognitive 
impairment, social environment and frailty with adverse health outcomes in patients 
with esophageal cancer. Furthermore, quality assessment of the studies was performed 
to identify potential factors that may impede external validity.
Given the high prevalence of geriatric impairments described in this review it is likely 
that systematic geriatric screening and a multidisciplinary approach could be of added 
value in the treatment of older patients with esophageal cancer. Patients who are at 
high risk for adverse outcomes can be identified and preventive measures, for example 
to prevent for a delirium or functional decline, could be taken. This benefit is already 
described in different patient populations [59, 60]. Furthermore, we advise that future 
observational studies should report their outcomes in such a way that a meta-analysis 
is possible.
Conclusion
Functional and cognitive impairment, depression and social isolation are prevalent in 
patients with esophageal cancer, and associate with adverse health outcomes. Geriatric 
measurements may guide decision-making and customize treatments, but more large 
studies are needed to explore the clinical usability.
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absTRaCT
background The aim is to describe the association of functional capacity and cognitive 
functioning with one-year mortality in older patients with cancer in the head and neck 
region.
Methods We performed a cohort study in which all patients aged 70 years and older, 
received a geriatric screening prior to treatment. Main outcome was one-year mortality.
Results 102 patients were included. Median age was 78.7 years (IQR) 72.3-84.5), 25% were 
cognitive impaired, 40% were malnourished, and 28.4% used a walking device. Overall, 
one-year mortality was 42.3%. Male gender (HR) 4.30; 95% CI 1.35-13.67), malnutrition 
(HR 2.55; 95% CI 1.19-5.16) and using a walking device (HR 2.80; 95% CI 1.13-6.93) were 
associated with higher mortality risk, independent of stage and comorbidities.
Conclusion In older patient with head and neck cancer the mortality rates are high. 
Nutritional status and mobility are determinants of one-year mortality, independent of 




Patients diagnosed with head and neck cancer (HNC) are, in case of curative intention, 
generally facing major treatment options, like extensive operation and/ or (chemo)ra-
diation therapy. Older patients in general are at higher risk for adverse health outcomes 
(such as delirium, complications and longer length of stay) after treatment, but the 
risk for HNC patients is even higher because of a high prevalence of previous excessive 
alcohol drinking and smoking [1-3] making this group more susceptible for cognitive 
[3, 4] and functional [5] decline. It could be important to make a careful selection of 
the patients who are suitable for the intensive treatment. In the USA it is expected that 
between 2010 and 2030 the incidence of oral cavity and pharyngeal cancer in patients 
aged 65 years and older will increase with 61% [6]. Besides, the five-year survival is 
poor with an estimated survival of 50% with a large variation between the different 
tumor localizations [7, 8]. However, limited evidence is available on the association of 
a geriatric assessment with adverse health outcomes and the role of assisting clinical 
decision-making in older patients with HNC.
Across a variety of (surgical) oncologic populations and cancer types, components of the 
geriatric assessment, such as cognition, functional status and social status, are predic-
tive for adverse health outcomes such as postoperative complications, institutionaliza-
tion after discharge and mortality [9, 10]. Several guidelines recommend for a form of 
geriatric assessments as part of routine preoperative care [11, 12]. A recent systematic 
review in older HNC patients showed that geriatric conditions were prevalent and in 
64% of the included studies there was a statistically significant association of geriatric 
impairments with a higher risk of adverse outcome [13]. However, cognitive function 
and objectively measured physical capacity were not assessed.
The aim of this study is to describe the association in older patients with cancer in the 
head and neck region of geriatric measurements, including functional capacity and 
cognitive functioning, with one-year mortality.
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MeThoDs
study design and setting
We performed a retrospective cohort study (from October 2014 until January 2017) in 
older patients presenting with cancer in the head and neck region in the Leiden Uni-
versity Medical Centre (LUMC). From October 2014, a routine clinical care pathway was 
implemented in which all older head and neck cancer patients were referred to the de-
partment of Gerontology and Geriatrics for a geriatric screening prior to treatment. The 
result of this geriatric screening was discussed in the multidisciplinary team. Patients 
were referred when aged 70 years and older, or younger but with multiple comorbidi-
ties, diagnosed with stage III-IV HNC, or diagnosed with a lower stage HNC but needing 
invasive treatment, for geriatric screening prior to their invasive treatment. In this study 
head and neck cancer was considered as cancer in the head and neck region needing 
invasive treatment by the head and neck surgeon. This includes cancer in the sinonasal 
or oral regions, nasopharynx, oropharynx, hypopharynx, supraglottic, the larynx, the 
salivary glands or the proximal oesophagus. But also patients with large or regionally 
metastasized dermal cancer, lymphoma, an unknown primary or a recurrent tumor were 
referred for geriatric assessment. Thyroid cancer patients are not included in this study, 
because in the Netherlands thyroid cancer is not treated by a head and neck surgeon. 
For the retrospective collection and analysis of the data from these patients, the Medical 
Ethical Committee of the LUMC issued a “certificate of no objection”.
Determinants
Collected demographics were age, gender, marital status and level of education. High 
education level was defined as university or higher vocational training and low educa-
tion is defined as elementary school, community college and secondary education. The 
Adult Comorbidity Evaluation-27 score (ACE-27) was calculated [14]. The ACE-27 has 
specifically been developed for cancer patients in general. This index contains 27 differ-
ent comorbidities from various organ systems. Grade 0 corresponds to no comorbidity, 
grade 1 to mild comorbidity, grade 2 to moderate comorbidity and grade 3 to severe co-
morbidity [15, 16]. Disease severity indicators consisted of tumor site, tumor stage and 
whether the tumor was a new primary tumor. Tumor stage was directly extracted from 
the medical record [17]. Geriatric measurements were the Katz Index of Independence 
in Activities of Daily Living (Katz ADL) [18], the Lawton Instrumental Activities of Daily 
Living (IADL)[19], the 6 Item Cognitive Impairment Test (6CIT) [20], the Mini Nutritional 
Assessment (MNA) [21] and the Identification of Seniors At Risk – Hospitalized Patients 
questionnaire (ISAR-HP) [22]. The Katz ADL score ranges from 0-6 and the Lawton IADL 
score ranges from 0-24, a higher score corresponds with more functional dependency. 
The 6CIT is a short cognition test [20] and has a maximum score of 28 points, in this 
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routine clinical care pathway, a score ≥8 is considered as abnormal, suggesting cognitive 
impairment. Nutritional status was assessed with the MNA questionnaire, a screening 
tool consisting of 6 questions to estimate the risk of malnutrition [21], a cut-off point of 
≤ 11 was used to define (the risk for) malnutrition. The ISAR-HP ranges from 0-5 and is a 
screening tool to assess the risk for development of functional decline. A cut-off point of 
≥2 points was used to define this risk [22]. Furthermore, the use of a walking device was 
extracted from the medical record.
outcome
The main outcome of this study was mortality at twelve months of follow-up after start 
of treatment. Mortality data were extracted from the municipal records.
statistical methods
Baseline characteristics are presented as mean with standard deviation (SD) in case of 
normal distribution, median with interquartile range (IQR) in case of skewed distribution 
or as numbers with percentages (%). Different groups were compared using the t-test 
for continuous normally distributed data, chi-square test for categorical data and the 
Mann-Whitney U test for skewed data. To investigate the association between baseline 
characteristics and mortality a Cox regression model was used. In the multivariable 
model (table 2) treatment intention was not used as a determinant, to avoid overcor-
rection, because treatment intention is based on all the other determinants. In the 
multivariable analysis reported in table 3 we stratified the analysis for curative intention. 
Hazard ratios with 95% confidence intervals (CI) were calculated and a p-value of <0.05 
was considered significant. All analyses were performed using SPSS (IBM version 23; IBM 
Corp., Armonk, New York, USA).
Results
A total of 102 older patients with head and neck cancer were included in the present 
study. Table 1 shows the baseline characteristics of this population. The median age was 
78.7 years (interquartile range (IQR) 72.3-84.5) and 71 patients (69.6%) were male. Mild 
or moderate comorbidity was observed in 71 patients (69.6%) and 25 patients (24.5%) 
had severe comorbidity. A minority of the patients were diagnosed with skin cancer in 
the head and neck region (24.5%). Most patients (n=72) had a newly diagnosed head 
and neck tumor (70.6%) and 62 patients (65.6%) had stage III-IV cancer. More than 25% 
of the patients had cognitive impairment, almost 40% had (risk for) malnutrition, more 
than 40% had an abnormal ISAR-HP and 28.4% of the included patients used a walking 
device.
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Table 1. Baseline characteristics of the total study population
Characteristics  Participants, n = 102
Patient characteristics
Age (years), median (IQR) 78.7 (72.3-84.5)
Male gender, n (%) 71 (69.6)
Married, n (%) 55 (53.9)
Educational level, n (%)
   Low 67 (75.3)
   High 22 (24.7)
ACE-27 score, n (%)
   No comorbidity 6 (5.9)
   Mild comorbidity 37 (36.3)
   Moderate comorbidity 34 (33.3)
   Severe comorbidity 25 (24.5)
Number of drugs, median (IQR) 6 (2.3-8)
BMI, median (IQR) 24.6 (21.6-26.9)
Smoking history, n (%) 82 (83.7)
Alcohol units/week, median (IQR) 5.0 (0-14)
Disease specific
Tumor site, n (%)
   Oral cavity 24 (23.5)
   Pharynx 24 (23.5)
   Larynx 9 (8.8)
   Salivary gland 8 (7.8)
   Skin of head and neck region 24 (24.5)
   Other1 13 (12.7)
New primary tumor 72 (70.6)
Stage grouping, n (%)
   Stage I-II 33 (34.4)
   Stage III-IV 62 (65.6)
Treatment goal, n (%)
    Curative






Cognitive impairment, n (%) 25 (25.3)
Functional dependent, n (%) 14 (13.7)
Dependent in IADL function, n (%) 10 (9.9)
Risk of malnutrition or malnourished, n (%) 40 (39.2)
Risk for functional decline after hospitalisation, n (%) 24 (41.4)
Use of a walking device, n (%) 29 (28.4)
Abbreviations: n=number, IQR= interquartile range, ACE-27=Adult Comorbidity Evaluation Score, 
MNA= Mini Nutritional Assessment, IADL = Independent Activities in Daily Living.
Data incomplete for: educational level (n=89), number of drugs (n=100), BMI (n=101), 
smoking history (n=98), alcohol consumption (n=97), stage of disease (n=96), 6-CIT score (n= 99), 
IADL score (n=101). 1 In the other group were included: unknown primary tumor, 
sinonasal tumor, proximal oesophagus tumors, lymphoma of head and neck and vestibular schwannoma
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Figure 1 shows the cumulative survival curve of all included patients. Within one year 
42.3% of the patients were deceased. Table 2 shows the risk of one-year mortality for 
baseline determinants for all included patients. In the univariable analysis several deter-
minants were associated with an increased mortality; a low BMI with a hazard ratio (HR 
0.89; 95% CI 0.83-0.95) compared to a higher BMI, stage III-IV (HR 4.12; 95% CI 1.61-10.60) 
compared to stage I-II and treatment with palliative intention (HR 5.16; 95% CI 2.74-
9.72) compared to curative intention. Also (risk for) malnutrition was associated with an 
increased mortality (HR 3.40; 95% CI 1.83-6.33) compared to no (risk for) malnutrition 
and also dependency in IADL functioning (HR 1.07; 95% CI 1.02-1.12) compared with 
no dependency. Independent factors for a higher risk for one-year mortality were male 
gender (HR 4.30; 95% CI 1.35-13.67), an abnormal MNA-score (HR 2.55; 95% CI 1.19-5.16) 
and the use of a walking device (HR 2.80; 95% CI 1.13-6.93).
Table 2. The association between baseline characteristics and mortality after one year of follow-up of all 
included patients. 
Variable univariable analysis Multivariable analysis
hR 95% CI p-value hR 95% CI p-value
Age 0.99 0.95-1.03 0.500 1.00 0.96-1.05 0.908
Male gender 1.58 0.78-3.20 0.207 4.30 1.35-13.67 0.014
Marital status
   Married Ref - -
   Single 1.00 0.58-1.82 0.992 - - -
ACE-27 score
   Score 0-1 Ref - - Ref - -
   Score 2-3 1.77 0.91-3.44 0.091 1.42 0.65-3.08 0.383
Number of drugs 1.00 0.92-1.07 0.790 0.97 0.89-1.07 0.586
BMI 0.89 0.83-0.95 0.001 - - -
Stage of disease
   Stage 0-II Ref - - Ref - -
   Stage III-IV 4.12 1.61-10.60 0.003 2.03 0.79-5.27 0.144
Goal of treatment
   Curative Ref - -
   Palliative 5.16 2.74-9.72 <0.001 - - -
Cognitive impairment 1.73 0.91-3.29 0.094 1.76 0.61-5.07 0.294
(risk for) malnutrition 3.40 1.83-6.33 <0.001 2.55 1.23-5.26 0.011
Functional dependent 1.07 0.93-1.18 0.436 - - -
Dependent in IADL function 1.07 1.02-1.12 0.010 1.07 0.97-1.17 0.197
Use of a walking device 1.77 0.95-3.29 0.070 2.80 1.13-6.93 0.026
Abbreviations: HR=hazard ratio, 95% CI = 95% confidence interval, ACE-27 = Adult Comorbidity Evaluation 
Score, 6-CIT = 6-Item Cognitive Impairment Test, MNA= Mini Nutritional Assessment, ADL = Activities in 
Daily Living, IADL = Independent Activities in Daily Living. Multivariate analysis was done with complete 










































































Figure 2 shows the sensitivity analysis in which we stratified the cumulative survival to 
treatment intention. After 12 months of follow-up 74.3% (n=26) of the patients treated 
with palliative intention were deceased in contrast to 25.4% (n=17) of the patients 
treated with curative intention. The median survival for the patients treated with pallia-
tive intention was 6.3 months. Table 3 shows the risk of one-year mortality for baseline 
determinants for the patients treated with curative intention. Independent factors for 
a higher risk for one year mortality were male gender (HR 27.64; 95% CI 1.56-490.1), 
(risk for) malnutrition (HR 6.81; 95% CI 1.84-25.22) compared to no (risk for) malnutrition 
and the use of a walking device (HR 6.93; 95% CI 1.58-30.46) compared with no use of a 
walking device.
Discussion
The main findings of this study are that the mortality rate is high, even in the patients 
treated with curative intent and that (the risk for) malnutrition and mobility were de-
terminants associated with one-year mortality, independent of tumor stage, age and 
comorbidity in older patients with cancer in the head and neck region.
Table 3. Independent determinants for one-year survival in curative treated patients
Variable Multivariable analysis 
HR 95% CI p-value
Age 1.04 0.95-1.14 0.353
Male gender 27.64 1.56-490.1 0.024
ACE-27 score
   Score 0-1 Ref - -
   Score 2-3 2.41 0.65-8.95 0.190
Number of drugs 1.00 0.86-1.16 0.990
Stage of disease
   Stage 0-II Ref - -
   Stage III-IV 0.77 0.19-3.02 0.703
Cognitive impairment 2.74 0.51-14.85 0.243
(risk for) malnutrition 6.81 1.84-25.22 0.004
Dependent in IADL functioning 1.05 0.88-1.24 0.590
Use of a walking device 6.93 1.58-30.46 0.010
Abbreviations: HR=hazard ratio, 95% CI = 95% confidence interval, ACE-27 = Adult Comorbidity Evaluation 
Score, 6-CIT = 6-Item Cognitive Impairment Test, MNA= Mini Nutritional Assessment, ADL = Activities in 
Daily Living, IADL = Independent Activities in Daily Living. Multivariate analysis was done with complete 
data for 60 patients. 
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In our study, several geriatric impairments were associated with one-year mortality, 
but after correcting for gender, age and disease specific determinants, only the use of 
a walking device was independently associated with one-year mortality. Our recently 
published systematic review reports that in 64% of the reported associations, a decline 
in functional or cognitive impairment, mood or social environment was associated with 
adverse outcomes [13]. Very little is known about the use and the predictive value of a 
geriatric assessment in HNC, because most of the studies included low patient numbers 
and therefore have a lack of power. In other fields of medicine a geriatric assessment is 
well established to guide decision-making or to identify unknown geriatric impairments 
(such as cognitive impairment and functional dependency), which can be taken into ac-
count before or during treatment [23, 24]. To our knowledge it is not previously reported 
that the use of a walking device is associated with one-year mortality.
In this cohort the one-year mortality rates are high: 42.3% overall in the included patients, 
but also 25% of the patients treated with curative intent are deceased within one-year. 
In general, the five-year survival in HNC patients is around 50% depending on tumor 
stage, tumor type and treatment intention [7, 8]. Treatment with curative intention can 
contain chemoradiation or an operation (depending the type of HNC) and followed by 
(chemo)radiation therapy when indicated. In patients aged 70 years and older, adding 
chemotherapy to radiotherapy does not contributed to higher survival rates [25, 26]. 
Life expectancy is obviously lower when getting older, and therefore could be taken in 
to account. The knowledge of the survival rates, the extensiveness of the treatment and 
the predictors reported in this study and in order to personalize the treatment plan for 
this vulnerable population, more research should be done.
We found a relative high prevalence of geriatric impairments. For example, a quarter 
of the included patients were cognitive impaired. Compared to the limited literature 
available, the proportion patient who are cognitively impaired reported in our study 
could potentially even be higher. Williams et al. describes 83 adults with HNC prior to 
treatment and reports that more than 50% were cognitively impaired [27]. The study of 
Bond et al. describes 70 HNC patients and reports around 47% of cognitively impaired 
patients [28]. So, probably the cognition test used in our study was not comprehensive 
enough to recognize subtle cognitive impairment. The clinical implications of cognitive 
impairment prior treatment are not well described in literature, but most likely nega-
tively affects HNC patients like in other fields of oncologic medicine [29]. In these fields it 
is known that being cognitive impaired prior to treatment gives a higher risk for adverse 
health outcomes such as toxicity, not able to finish treatment, side effects and mortality 
[28, 30]. Besides, it is probably more difficult for patients with cognitive dysfunction to 
weigh the risk and benefits for cancer treatment, which impedes good shared decision 
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making, to comply with the treatment plan and to adequately ask for medical attention 
if necessary. Therefore it could be informative for the patient as well as the treating spe-
cialist to have insight in the cognitive status and to take this information into account.
There are some limitations to our study. First, the included study population was rela-
tively small. Second, the outcome of this study was mortality, while remaining functional 
and cognitive independent and quality of life would be also interesting outcomes to 
assess. Finally, the tumor types in the present study were heterogeneous. Strengths of 
this study include the relatively unselected patient cohort which has as result that the 
included patients in this study were a reflection of the older HNC patient seen in clinical 
practice. All included participants underwent a comprehensive geriatric assessment. 
And this study complements the, until now limited, available literature.
Conclusions
In older patient with head and neck cancer the mortality rates are high. Nutritional sta-
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background The prevalence of impaired cognitive functioning in older patients with 
end stage renal disease (ESRD) is high. We aim to describe patterns of memory, execu-
tive function or psychomotor speed and to identify nephrologic, geriatric and neurora-
diologic determinants associated with cognitive impairment in older patients reaching 
ESRD who have not yet started with renal replacement therapy (RRT).
Methods the Cognitive Decline in Older Patients with ESRD (the COPE-study) is a pro-
spective cohort study including 157 participants aged 65 years and older reaching ESRD 
(eGFR ≤20 ml/min/1.73 m2) prior to starting with RRT. Apart from routinely collected 
clinical parameters related to ESRD, such as vascular disease burden and parameters of 
metabolic disturbance, patients received a full geriatric assessment, including extensive 
neuropsychological testing. In a subgroup of the patients (n=93) a brain MRI was per-
formed.
Results The median age was 75.3 years. Compared to the normative data of neuropsy-
chological testing participants memory performance was in the 24th percentile, execu-
tive function in the 18th percentile and psychomotor speed in the 20th percentile. In-
dependent determinants of impairment in memory, executive and psychomotor speed 
were high age, low educational level and low functional status (all p-values <0.003). A 
history of vascular disease (p= 0.007) and more white matter hyperintensities on brain 
MRI (p= 0.013) were associated with a lower psychomotor speed.
Conclusion Older patients reaching ESRD have a high prevalence of impaired memory, 
executive function and psychomotor speed. High age, low education, low functional 
status, frailty, higher burden of white matter hyperintensities on MRI and a history of 
vascular disease were determinants. The patterns of cognitive impairment and brain 




Older patients reaching end stage renal disease (ESRD) are, compared to younger 
patients, at increased risk for adverse health outcomes in general [1] and for impaired 
cognitive functioning [2], with a high prevalence ranging from 30% to around 87% in 
dialysis patients [3, 4]. Cognitive impairment has a major impact on outcomes in (older) 
patients receiving renal replacement therapy (RTT)[5]. Understanding patterns and 
determinants of cognitive functioning in the phase before RTT may guide informed 
treatment decisions and ultimately minimize the risk for further cognitive decline.
Several pathophysiological mechanisms are suggested for the high prevalence of im-
paired cognitive function in patients reaching ESRD such as vascular, neurodegenerative 
and metabolic processes [6-8]. The brain and kidney are both low resistance end organs, 
exposed to high blood flow and vulnerable to vascular damage [9]. If vascular damage 
plays a role in developing the kidney disease, this may also affect the cerebral vascula-
ture, leading to structural brain abnormalities and cognitive impairment, mostly in the 
executive domains and psychomotor speed [10]. Accumulation of uremic toxins may 
cause cerebral endothelial dysfunction, and lead to neurodegenerative damage in brain 
regions that play a dominant role in cognitive domains of attention and speed [11]. Only 
a few studies report on the systematic assessment of patterns of cognitive functioning 
and their determinants in older patients reaching ESRD with only little attention on the 
actual brain damage observed on brain MRI [12].
In the Cognitive decline in Older Patients with ESRD (COPE) study [13] we aimed to 
describe patterns of memory, executive function or psychomotor speed and to iden-
tify nephrologic, geriatric and neuroradiologic determinants associated with cognitive 





The full design of the COPE study, methods and rationale have been published previously 
[13]. In brief, the COPE study is a prospective, multicentre cohort study in four hospitals in 
the Netherlands in patients aged 65 years and older reaching ESRD (estimated glomeru-
lar filtration rate (eGFR) ≤ 20 ml/min/1.73 m2), and attending the pre-dialysis outpatient 
between April 2014 and December 2017. As part of routine pre-dialysis nephro-geriatric 
work-up, a comprehensive geriatric assessment (CGA), physical examination, laboratory 
investigation, neuropsychological testing and a brain MRI scan (in case there was no 
contra-indication) were performed. The study protocol was approved by the medical 
ethics committee (METC) of all participating centres.
Routine renal care
Of patients attending the pre-dialysis outpatient clinic, the following clinical parameters 
were routinely collected: kidney function, metabolic state (urea, phosphate, calcium) 
and parameters on vascular status (blood pressure, ankle/arm index). eGFR was esti-
mated glomerular filtration rate using the Modified of Diet in Renal Disease (MDRD)[14] 
or Chronic Kidney Disease Epidemiology Collaboration (CKD-epi)[15] depending on the 
method used in the different hospitals. Patients were allocated to in vascular and non-
vascular cause of kidney disease according to the ERA-EDTA primary renal diagnosis 
code, assessed by the treating nephrologist. Vascular disease burden was determined 
as the cause of the kidney disease (vascular versus non-vascular), ankle-brachial index, 
the presence of diabetes and the history of vascular disease (previous of myocardial 
infarction and/or cerebral vascular incident (CVA) and/or peripheral vascular disease). 
We considered urea, phosphate and calcium as parameters of metabolic disturbance.
Geriatric work-up
As part of the nephro-geriatric work-up, all patients underwent a comprehensive geriat-
ric assessment (CGA). For a more detailed description of the tests used in the COPE study, 
see the previously published study protocol [13]. Briefly, the CGA work-up consisted the 
following tests; to asses nutrition, the Normal Subjective Global Assessment (SGA) score 
[16] and the SNAQ score [17] were administered. To asses frailty the Fried Frailty Index 
(FFI) was used and a score of ≥3 was considered as frail [18]. Functional dependence 
was assessed by the Groningen Activity Restriction Scale (GARS), with higher scores are 
indicative of increased dependence (range 18-72)[19], and the The Lawton Instrumental 
Activity of Daily Living (IADL) score, with a score ≥11 being considered as functionally 
dependent [20]. Furthermore, to assess physical capacity the handgrip strength and 




Trained geriatric or dialysis nurses administered a standardized neuropsychological 
test battery. It was designed to assess different domains of cognitive functioning such 
as global cognition, visuoconstruction, memory, executive function and psychomotor 
speed. The test battery has been successfully used in several study cohorts over the past 
20 years [21-23] and is based on clinical experience, scientific literature and relevance 
for clinical interference [21]. To test global cognition the Mini Mental State Examination 
(MMSE) was used, ranging from 0-30 points with higher scores indicating better cogni-
tive performance [24]. Clock drawing was used to assess visuoconstructive abilities and 
executive function, with scores ranging from 0-14 points and higher scores indicating 
better performance [25, 26]. Memory, was tested with tested with the 15-Word Verbal 
Learning Test (WVLT) both immediately (total score after five trials) and delayed recall 
was used, higher scores indicating better function [27]. To test memory reproduction 
the Visual Attention Test (VAT) was used, with higher scores indicating better function 
[28]. Executive function assessed with visual attention and task switching were tested 
with the Trail Making Test A and B (TMT-A and TMT-B), with lower scores indicating better 
function [29]. To distinguish between processing speed or cognitive (in)flexibility as an 
explanation of the test result the score on the TMT-B was corrected for the score on the 
TMT-A. Also the Stroop Colour Word Test (SCWT) was used, with lower scores indicating 
better function [30-31]. To distinguish between processing speed and cognitive inhibi-
tion as an explanation of the test result the score on the Stroop III (interference card) was 
corrected for the score on the Stroop II (colour naming card). To test psychomotor speed 
the Letter Digit Substitution Test (LDST), Stroop II and TMT-A was used. For the LDST 
the number of correct substitutions made in 60 seconds was used, with higher scores 
indicating better function [32].
normative data of neuropsychological testing
To compare the cognitive test results of the current study with a general population, 
Dutch normative data for neuropsychological tests corrected for age, gender and educa-
tional level were used [33]. These normative data are commonly used in the Netherlands 
for clinical ratings in daily practice and were available for the 15-WVLT, TMT-A, TMT-B 
and the SCWT. The norms were based on between 300-1000 healthy participants aged 
14-90 years.
MRI of the brain
As part of routine nephrogeriatric work-up a brain MRI was performed in all patients 
without a contra-indication for MRI. Brain MRI scans were acquired on a Philips Ingenia 
3T scanners at the LUMC (Philips Medical Systems, Best, The Netherlands) according to 
a standardized scanning protocol. The scanning protocol included T1-weighted images 
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(repetition time (TR) = 8.2ms; echo time (TE) = 4.5ms; flip angle 8°, voxel size 1x1x1mm3), 
fluid-attenuated inversion recovery (FLAIR) images (TR = 4800 ms; TE = 313 ms; inversion 
time (TI) = 1650 ms; voxel size 1.11x1.11x1.11mm3) and susceptibility-weighted imaging 
(TR=45ms; TE 31ms; flip angle 13°; voxel size 0.8x0.8x1.6mm3). The brain MRI scans were 
scored for markers of small vessel disease (white matter hyperintensities) and lacunes of 
presumed vascular origin and microbleeds) according to the STRIVE criteria [34]. White 
matter hyperintensities were assessed by the Scheltens scale [35].
statistical methods
Baseline characteristics are presented as mean with standard deviation (SD) in case of 
normal distribution, median with interquartile range (IQR) in case of skewed distribu-
tion or as number (n) with percentages (%). Mean functioning on the different cognitive 
domains (memory, executive function and psychomotor speed) are presented as per-
centiles (mean with IQR), according to the normative data neuropsychological testing (see 
above). To assess determinants of cognitive functioning in different domains, different 
cognitive tests are stratified in tertiles and mean scores of the different determinants are 
calculated over the tertiles of cognitive functioning, presented as mean (standard error 
(SE)). Crude and adjusted p-values were calculated with univariable and multivariable 
linear regression models, respectively, with the continuous score of cognitive perfor-
mance as dependent variable. In multivariable model we adjusted for age, gender, 
educational level, in order to make a balanced comparison between the tertiles. The MRI 
abnormalities were also assessed as determinant of cognitive function. The p-values are 
presented crude and adjusted (again for age, gender and educational level). All analyses 
were carried out using SPSS (IBM version 23; IBM Corp., Armonk, New York, USA).
ResulTs
Table 1 shows the baseline characteristics of the study population. The study population 
consisted of 157 participants with a median age of 75 years and 103 (66%) participants 
were male. At study enrolment, the mean eGFR was 16.2 ml/min (standard deviation 
(SD) 4.4) and over the past three years the mean decline in eGFR was 9.1 ml/min (SD 8.0). 
In 99 (63%) patients a vascular cause, mainly hypertension or diabetes mellitus, was the 
origin of their primary kidney disease. Almost half of the participants (n=74; 47%) had 
a history of vascular disease. According to the Fried Frailty Index (FFI) 37 (25%) patients 
were frail. Functional dependence, according to an Instrumental Activities of Daily Liv-
ing (IADL) score of ≥11, was present in 8 (5%) of the patients.
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Table 1. Baseline characteristics of the included study population
Patient characteristics
Total 157
Age, median (IQR) 75.3 (70.8-80.8)
Male gender, n (%) 103 (65.6)
Caucasian origin, n (%) 138 (89.0)
Married/living together, n (%) 94 (61.4)
Higher Educational level, n (%) 48 (30.6)
Current smoking 23 (15.0)
Alcohol consumption 77 (50.3)
Disease specific
eGFR at study enrolment, mean (SD) 16.2 (4.4)
Δ eGFR (ml/min), mean (SD)* 9.1 (8.0)
Primairy kidney disease
     Non-vascular cause, n (%) 56 (35.7)
     Vascular cause, n (%) 99 (63.1)
Diabetes mellitus, n (%) 63 (40.1)
(history of ) malignancy, n (%) 47 (29.9)
History of vascular disease, (n%) 74 (47.4)
Ankle-brachial index (right), mean (SD) 0.96 (0.23)
Medication use
Polypharmacy (the use of ≥5 medications), n (%) 139 (89.7)
Glucose lowering medication, n (%) 54 (34.4)
Antihypertensive medication, n (%) 145 (92.4)
Diuretics, n (%) 94 (60.3)
Cholesterol lowering drugs, n (%) 112 (71.3)
Vitamin D supplement, n (%) 131 (83.4)
nutrition status
Normal Subjective Global Assessment (SGA) score 42 (49.4)
SNAQ score
     Malnourished 8 (10.7)
     Risk for malnutrition 9 (12.0)
BMI, median (IQR) 27.4 (24.6-30.9)
Special diet, n (%) 127 (83.0)
Geriatric assessment
Frail according to FFI, n (%) 37 (24.5)
Functional dependence by GARS-score, mean (IQR) 26 (20.0-35.0)
Dependent in IADL function, n (%) 8 (5.0)
Handgrip strength (kg), mean (SD)
     Females 17.2 (6.3)
     Males 29.4 (8.1)
Walking speed, mean (SD) (m/s) 1.13 (0.98)
*Δ eGFR= difference between eGFR three years before and at study enrolment. Abbreviations: IQR= inter-
quartile range, eGFR= Estimated glomerular filtration rate, SNAQ= Short Nutritional Assessment Question-
naire, BMI= body mass index, FFI= Fried Frailty Index, GARS-score= Groningen Activity Restriction Score, 
IADL= Instrumental Activities of Daily Living. Data complete for; race (n=155), level of education (n=153), 
marital status (n=153), smoking and alcohol consumption (n=153), eGFR (n=151), primary kidney disease 
unknown=2, polypharmacy (n=155), diet (n=153), SGA-score (n=85), SNAQ=score (n=75), Fried Frailty In-




Supplemental table 1 reports the performance on the global cognitive function and 
different cognitive domains. The population had a median Mini-Mental State Examina-
tion (MMSE) of 28 out of 30 points (IQR 27-29). Mean functioning on the memory test 
(15-Word Verbal Learning Test (15-WVLT)) was in the 24th percentile (IQR 10-54) with a 
mean score of 31.2 words remembered (SD 9.9). The mean functioning on the executive 
function (Trail Making Test B (TMT-B)) was in the 18th percentile (IQR 3-54) with a mean 
score 177.4 seconds (SD 79.5). The mean functioning on psychomotor speed (Letter 
Digit Substitution Test (LDST) was in the 20th percentile (IQR 10-50) with a mean score of 
21.7 correct substitutions (SD 6.9).
Table 2 and 3 and in supplemental table 2 we report the determinants of three differ-
ent cognitive domains, namely memory, executive function and psychomotor speed, 
respectively. In all three cognitive domains, as expected, older age and lower level of 
education were significantly associated with cognitive impairment (all p-values ≤0.007). 
For example, the patients who performed in the worst tertile in memory function, 
compared to the best tertile, were on average 5 years older (p<0.001) and had a higher 
chance of having received a lower educational level (for memory function: 20% versus 
33%, p=0.001).
Table 2 shows the determinants of the memory domain. After adjusting for age, gender 
and educational level a higher level of functional dependence (IADL-score) was sig-
nificantly associated with a more impaired memory function (p=0.003). Patients who 
performed in the worst tertile of memory function were more functionally dependent 
compared to the patients who performed in the best tertile (mean IADL-score of 4.6 (SE 
0.6) versus a mean IADL-score 2.0 (SE 0.4); p<0.003). Having a history of vascular disease 
associated with a more impaired memory function, although the association lost statis-
tical significance after adjustment for age, gender and educational level. Parameters of 
metabolic disturbance were not associated with an impaired memory function.
Table 3 presents the determinants of the cognitive domain of executive function. After 
adjusting for age, gender and educational level, a higher level of functional dependence 
(p<0.001), the presence of frailty (p=0.001) and a lower handgrip strength (p=0.020) were 
significantly associated with a more impaired executive functioning. For example, in the 
tertile with the worst executive function, the presence of frailty was higher compared to 
the best tertile (mean Fried Frailty Index of 2.1 (SE 0.2) versus a mean Fried Frailty Index 
1.0 (SE 0.2); p=0.001). Having a history of vascular disease associated with an impaired 
executive function, although the association lost statistical significance after adjust-
ment for age, gender and educational level. Parameters of metabolic disturbance were 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplemental table 2 shows the determinants on the cognitive domain of psychomotor 
speed. After adjusting for age, gender and educational level, a higher presence of frailty 
(p=0.001), a higher level of functional dependence (p<0.001) and a lower handgrip 
strength (p=0.026) were significantly associated with impaired performance on psycho-
motor speed. For example, the patients who performed in the worst tertile of psycho-
motor speed had a lower handgrip strength compared to the patients who performed 
in the best tertile (mean handgrip strength of 24.9 (SE 1.3) versus a mean handgrip 
strength 26.8 (SE 1.4); p=0.026). After adjusting for age, gender and educational level, 
having a history of vascular disease was associated with an impaired performance on 
psychomotor speed (p=0.007). Again, parameters of metabolic disturbance were not 
associated with an impaired performance psychomotor speed.
The cerebrovascular MRI features in a subpopulation (n=93) are presented in Supple-
mental table 3. The mean Scheltens score of the white matter hyperintensities was 15.8 
(SD 7.6). Lobar microbleeds were present in 37 (40%) of the included participants and 
19 (20%) participants had non-lobar microbleeds. Lacunes of presumed vascular origin 
were present in 44 (48%) participants. Table 4 shows which brain MRI abnormalities are 
determinants of the different neuropsychological domains memory, executive function 
and psychomotor speed. When adjusting for age, gender and educational level, only 
a higher burden of white matter hyperintensities was significantly associated with 
worse psychomotor speed. Patients who performed in the worst tertile of psychomotor 
speed on average had more white matter hyperintensities compared to patients who 
performed in the best tertile (mean white matter hyperintensities of 18.6 (SE 1.6) versus 
a mean white matter hyperintensities 14.6 (SE 1.2); p=0.013). A trend was observed for 
the association between a higher burden of white matter hyperintensities and lower 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The main findings of the present study are twofold. First, impaired cognitive function is 
highly prevalent in patients reaching ESRD not yet started with RTT and are present in 
the domains of memory, executive function and psychomotor speed. Second, determi-
nants of a worse cognitive function in the domains memory, executive and psychomotor 
speed were high age, low education, low functional status, frailty, higher burden of white 
matter hyperintensities on MRI and a history of vascular disease, whereas parameters of 
metabolic disturbance were not.
In the present study, older patients reaching ESRD performed worse on all cognitive do-
mains tested in comparison to the general population. This is consistent with a study in 
younger patients at a pre-dialysis clinic in which impairments in psychomotor efficiency 
and processing speed were more evident than impairments in the domains of learning 
efficiency or attention and working memory[36]. Only one other study [37] reported on 
older patients with chronic kidney disease (N=385), with median creatinine clearance 
of 19 ml/min. This study also found deficits in all cognitive domains, with the largest 
deficiencies found in recall, attention and executive function. We found that determi-
nants of a worse cognitive function in the domains memory, executive and psychomo-
tor speed were high age, low education, low functional status, frailty, higher burden of 
white matter hyperintensities on MRI and a history of vascular disease. In different other 
populations with CKD, age, history of falls, functional status and a history of vascular 
disease were previously described determinants associated with impaired cognition [6, 
37]. Literature describes that geriatric impairments, such as dependency in activities of 
daily living (ADLs) and cognitive impairment, are also prevalent in younger patients with 
ESRD [38, 39]. The association between white matter hyperintensities and an impaired 
cognitive function, particularly in impairment in attention, executive function and 
information processing speed, has also been described in older community dwelling 
and hospitalised patients [40-42]. In our study, parameters of metabolic disturbance 
(urea, phosphate, calcium) were not associated with a worse cognitive function. There 
were conflicting results reported on the association of metabolic determinants and 
the association with a worse cognitive function [11, 43]. In summary, the patterns and 
determinants of cognitive impairment and the neuroradiological findings in our study 
population are in line with the previous limited literature.
There are several possible pathophysiological mechanisms that could explain the pat-
terns and determinants of cognitive impairment and the neuroradiological findings in 
the older patients with ESRD described in our study. First, it could be that ESRD and 
cerebral vascular damage, are endpoints of the same pathophysiological pathway. 
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Both the brain and kidney share similar vascular anatomy, as low resistance end organs 
exposed to high volume blood flow into their small vessels, and both have an auto-
regulatory system. Because of this unique system, small vessels in kidney and brain, both 
afferent arterioles and deep perforating arterioles, are particularly prone to be injured 
by systemic hypertension and other vascular disease [44] as well as by damage due 
to endothelial dysfunction. Small vessel disease can affect both kidney and the brain, 
white matter hyperintensities is considered as a neuroradiological marker for small 
vessel disease, which could explain the correlation between an impaired renal function 
and MRI markers of cerebral small vessel disease found in earlier studies [45]. However, 
extensive research on brain, perfusion and cardiac structure in older ESRD patients is 
scarce. Second, the high burden of vascular and metabolic morbidity in patients with 
ESRD lead to a higher biological age, resulting in different phenotypes such as prema-
ture vascular aging, muscle wasting, bone disease, cognitive dysfunction and frailty [39]. 
Taken together, the patterns of cognition and neuroradiological imaging are suggestive 
of vascular cognitive impairment in older patients with ESRD. Further research is needed 
to unravel the exact underlying pathophysiological mechanism.
Our results could have some clinical implications. When patients reach ESRD several 
treatment options, such as RRT including dialysis or transplantation or conservative 
treatment, are considered. When making treatment decisions, it can be important to 
have insight into the cognitive function of the patient for several reasons. First, cognitive 
impairment is independently associated with increased mortality, also in patients on 
RRT [4, 46]. Second, patients with cognitive impairment in general have a higher risk for 
adverse health outcomes such as delirium. Third, shared decision-making is leading in 
the process of decision-making when RTT is considered, and it is known that an impaired 
cognitive functioning can affect decision-making capacity [47].
There are several limitations of the current study. First, the study is integrated in routine 
clinical care and probably has some patient selection bias. It could be that the patients 
in worse condition were less likely to participate, which could result in an underesti-
mation of the observed prevalence of cognitive impairment. Second, the study has a 
relatively small group, which could cause a lack of power. Third, the present analysis 
reports the cross-sectional association between several determinants and cognition as a 
consequence that a causal association cannot be established. Our study also has several 
strengths. First, to our knowledge this is the first study in which cognitive function is de-
scribed so extensively in combination with brain MRI’s in an older population reaching 
ESRD. Second, the patients included in this study all have a eGFR < 20ml/min and are not 
on RRT yet, a study population that previously only received limited scientific attention. 
Third, this study focusses exclusively on older patients (included median age of 75.3 
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(IQR 70.8-80.8)), while it is known that older individuals very often do not participate in 
clinical trials due to exclusion criteria.[48, 49] With the limited exclusion criteria applied 
in the COPE-study, the included study population reflects the patients in daily clinical 
practice.
ConClusIon
Older patients reaching ESRD have a high prevalence of impaired memory, executive 
function and psychomotor speed. High age, low education, low functional status, frailty, 
higher burden of white matter hyperintensities on MRI and a history of vascular disease 
were determinants. The patterns of cognitive impairment and brain changes on MRI are 
suggestive of vascular cognitive impairment.
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     MMSE score (points), median (IQR) 28 (27-29)
Visuoconstruction
     Clock drawing, mean (IQR) 12 (11-13)
Memory
     15-Word Verbal Learning Test (words remembered)
           Immediate recall score, mean (SD) 31.2 (9.9) 24 (10-54)
           Delayed recall score, mean (SD) 5.8 (3.2) 22.5 (9.5-58)
     Visual Association Test (pictures remembered) , median (IQR) 12 (11-12) 29.0 (20-29)×
executive function
     TMT-B (sec), mean (SD)¥ 177.4 (79.5) 18 (3-54)
     TMT-B (sec) corrected for TMT-A 27 (12-58)
     Stroop III (sec), mean (SD) 172.6 (79.6) 18 (5-38)
     Stroop III (sec) corrected for Stroop II (sec), mean (SD) 88.9 (70.2) 46 (24-69)
Psychomotor speed
     LDST (correct in 60 sec), mean (SD) 21.7 (6.9) 20 (10-50)
     TMT-A (sec), mean (SD) 69.3 (38.5) 24 (6-56)
     Stroop II (sec), mean (SD) 83 (28.9) 16 (4-31)
*Corrected for age, gender and educational level. 
Abbreviations: IQR=  interquartile range, 15-WVLT= 15-Word Verbal Learning Test, TMT= Trail Making Test, 
Stroop III= Stroop Color Word Test III, LDST= Letter Digit Substitution Test. Data incomplete for: 15-WVLT 
(n=155), VAT (n=155), 
TMT (n=153), STROOP (n=151), Clock drawing (n=157). ¥: 16 patients did not completed the total test. 
They have been assigned the maximum number of 300 seconds. ×: 110 patients had the maximum score 
ending in ≥29th percentile. 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































supplemental Table 3. Cerebrovascular MRI features in the study population
MRI feature (n=93) Prevalence
Presence of microbleeds, n (%)
     Lobar 37 (39.8%)
     Non-lobar 19 (20.4%)
Presence of lacunes*, n (%) 44 (47.3%)
Total  white matter hyperintensities  (Scheltens score), mean (SD) 15.8 (7.6)
*Both gliotic and hemorrhagic parenchymal defects in the supratentorial white matter, the brain stem and 
basal ganglia.
Data complete for: microbleeds (lobair (n=93), non-lobair and cerebellair (n=92)), lacunes (n=93)
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absTRaCT
objectives Self-Rated Health (SRH) is an important Patient Reported Outcome (PRO), 
but little is known about SRH after a visit to the Emergency Department. We investi-
gated the determinants of decline in SRH during three months after an ED visit in older 
patients.
Design This was a multi-center prospective cohort study including acutely presenting 
older (≥70 years) patients in the ED (the Netherlands). Patients were asked to self-rate 
their health between 0-10. The main outcome was a decline in SRH defined as a transi-
tion of a SRH ≥6 to a SRH <6 three months after the patient’s visit to the ED.
Results Three months after the ED visit 870 patients had a stable SRH (71.4%) and 209 
patients declined in SRH (11.5%). Independent predictors with a decline in SRH were: 
male gender (OR 1.84) living alone (OR 1.58), living in residential care or nursing home 
(OR 2.76), number of different medications (OR 1.08), using a walking device (OR 1.73), 
and the Katz-ADL score (OR 1.23). Patients with functional decline three months after 
an ED visit, show a steeper decline in mean SRH (0.68 points) than patients with no 
functional decline (0.12 points, p<0.001).
Conclusion Decline in SRH after an ED visit in older patients is at least partly dependent 
on factors of functional capacity and functional decline. Preventive interventions to 
maintain functional status may be the solution to maintain SRH, but more research is 




Older patients present to the Emergency Department (ED) more frequently than younger 
patients [1, 2], and often experience adverse health outcomes after an ED visit [3]. Within 
3 months after an ED visit, 30% of the older patients experienced functional decline and 
around 10% died [4]. Besides mortality, Patient Reported Outcome (PROs) are more and 
more an outcome of interest in medicine [5]. PROs are measurements of health, reported 
by the patient, and can include physical and mental symptoms, functioning, self-rated 
health (SRH) and quality of life (QOL) [6, 7]. Self-rated health is a subjective assessment in 
which individuals rate the current status of their health. But, there are only a few reports 
on SRH and its determinants in older patients visiting the ED.
SRH can be simply assessed with a single question and there is widespread agreement 
that this single question provides useful information on how patients perceive their 
overall health status [8, 9]. SRH is mostly evaluated in community-dwelling older adults 
[10] as well in patients with cancer [11] and is associated with mortality and functional 
decline [10]. To our knowledge, there is only one study focussing on SRH in the older 
adult presenting to the emergency department [12], which reports that SRH predicts 
functional decline and mortality. By identifying determinants which are consequently 
associated with SRH, clinicians could intervene on those and therewith maintain SRH. 
However, it is currently unknown how SRH develops after an ED visit and which determi-
nants are associated with a decrease in SRH in the three months after the ED visit.
In the current study, we aim to identify the determinants of SRH at presentation at the 
ED, to describe the change of SRH after an ED visit and to identify the determinants of 
a decline in SRH three months after an ED visit. We performed an analysis in a prospec-
tive study of patients aged 70 years and older presenting to the EDs of two different 
hospitals in the Netherlands.
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MeThoDs
study design and setting
We analysed the data from the Acutely Presenting Older Patient (APOP) study. The full 
study design and methods are published previously [4]. In short, this was a prospective 
follow-up study at the ED of the Leiden University Medical Center (LUMC) and Alrijne 
Hospital in the Netherlands performed between September to November 2014 (LUMC) 
and March to June 2015 (Alrijne Hospital). Patients aged 70 years and older and present-
ing for the first time in the study period were considered eligible. The following patients 
were excluded: being triaged with highest urgency (code red), patients who were not 
able to approach due to an unstable medical condition, when there was lack of permis-
sion of the nurse or physician to enter the room for any reason, an impaired mental 
status without an authorised relative to provide informed consent. Also, patients with 
a language barrier and patients who left the waiting room were not eligible. Written 
informed consent was obtained from all participants. The medical ethics committee of 
the LUMC waived the necessity for formal approval of the present study as it was part of 
the routine care.
Data collection
Completion of the questionnaire was ideally 30 to 45 minutes after arrival because by 
then the patients were no longer occupied, the questionnaire took 5 to 10 minutes. A 
representative was permitted to answer the questions when the patient was unable to 
provide answers, with exception for the cognition test and the self-reported quality of 
life questions.
baseline
Collected demographics were age, gender, living arrangement and level of education. 
Living arrangement could be independent alone or with others, or living in a nursing or 
residential care home. High education level was defined as university or higher voca-
tional training and low education is defined as elementary school, community college 
and secondary education. Disease specific includes three items: reference by ambulance, 
the triage category by the Manchester Triage System and chief complaint, representing 
the disease severity. Chief complaint was classified as minor trauma, cardiopulmonary 
symptoms (chest pain and dyspnea), abdominal pain, malaise, collapse and other (e.g. 
major trauma, psychiatric complaints and other). Geriatric measurements were the 
Katz Index of Independence in Activities of Daily Living (Katz ADL)[13] and the 6 Item 
Cognitive Impairment Test (6CIT). The Katz ADL score ranges from 0-6 and a higher score 
corresponds with more dependency, and gives an impression of the level of functioning 
two weeks prior to the ED visit. The 6CIT is a short cognition test and is validated in a 
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Dutch population against the Mini Mental State Examination (MMSE)[14], the 6CIT has 
a maximum score of 28 points and with a cut-off ≥ 11 indicating cognitive impairment 
(MMSE <24). In our analysis we defined an impaired cognition as an abnormal score on 
the 6CIT and/or a diagnosis of dementia. The number of different medications, a history 
of diagnosed dementia and the use of a walking aid were assessed by questioning the 
patient or representative.
self-reported health related quality of life questionnaire (sRh)
To assess SRH a modified numeric rating scale was used, compared to the Cantril’s Lad-
der, in which patients self-rate their health related quality of life. Participants were asked 
to score their general health during the last month excluding the reason of their visit 
to the ED, with zero being the worst and ten being the best imaginable situation. Three 
months after the ED visit, the participants were contacted by phone and asked to score 
their general health during the last month. At baseline only the patient was asked to 
give a score, but during follow-up also a proxy was allowed to give a score in case the 
patient was unable to provide an answer. During follow-up there were 131 (n=8.7%) 
proxy’s providing a SRH score on behalf of the included patients.
outcome
The main outcome was a decline in SRH defined as the transition of a sufficient SRH ≥6 
at baseline to a SRH <6 three months after the visit to the ED. The reason for this dis-
tinction is that in some European countries, including the Netherlands, grading scales 
range from 0-10 and a 6 or higher is considered as sufficient. Secondary outcome was 
functional decline which was defined as an increase of one or more points in Katz ADL 
score or new institutionalisation defined as a higher level of living arrangement at three 
months after the ED visit. Three months after the ED visit the patient was contacted by 
telephone. In case of no response a letter with the follow-up questions was sent.
statistical methods
Baseline characteristics are presented as mean with standard deviation (SD) in case of 
normal distribution, median with interquartile range (IQR) in case of skewed distribution 
or as numbers with percentages (%). Different groups were compared using the t-test 
for continuous normally distributed data, chi-square test for categorical data and the 
Mann-Whitney U test for skewed data. To investigate the association between baseline 
characteristics and a decline in SRH we used univariable and multivariable regression. 
Odds ratios with 95% confidence intervals (CI) were calculated and a p-value of <0.05 
was considered significant. Two sensitivity analysis were performed, one in which we 
defined a decline in SRH as a decrease of 2 or more points three months after an ED 
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visit. In the other sensitivity analysis we assumed all patients with no SRH at 3 months 
as having a decline in SRH. All analyses were performed using SPSS (IBM, version 23).
ResulTs
During the inclusion period a total of 2192 older patients presented to one of the two 
ED’s, 227 patients were excluded, resulting in 1965 eligible patients. Of these, 188 pa-
tients were missed for inclusion, 145 refused informed consent and from 130 there was 
no baseline SRH available. This led to a study population of 1502 patients (see Figure, 
Supplemental Digital Content 1, which demonstrates the flowchart). Figure 1 shows the 
different groups used in the analyses. At baseline, we divided the groups in patients with 
sufficient to good SRH (SRH ≥6; n=1219, 81.2%) and patients with an insufficient SRH 
(SRH <6; n=283, 18.8%).
Table 1 shows the baseline characteristics of the study population. The median age was 
79 years (interquartile range (IQR) 74-83) and 732 patients (48.7%) were male. More than 
half of the patients lived independently with others (n=854, 56.9%) and 545 patients 
(36.3%) lived alone. The median Katz ADL score at baseline was 0 (IQR 0-1) and 267 
(17.8%) patients had an impaired cognition. As shown in Table 1, the patients with a 
sufficient to good SRH (SRH ≥6) at baseline, differed significantly from the patients with 
an insufficient SRH (SRH <6) at baseline. Compared to the patients with a sufficient SRH 
at baseline, the patients with an insufficient SRH at baseline more often had the need of 
hospitalisation (56.9% vs 43.2%; p<0.001), used more medication (median 5 (IQR 3-7) vs 
fig 1: Flowchart of distribution of groups for analysis.




7 (IQR 4-10); p<0.001), used a walking device more often (36.3% vs 55.5%; p< 0.001), had 
a higher Katz-ADL score (median 0 (IQR 0-1) vs 1 (IQR 0-2); <0.001) and more patients 
had an impaired cognition (16.2% vs 24.7%; p<0.001). Independent factors associated 
with an insufficient SRH at baseline are: age, presentation with abdominal pain or mal-
aise, number of different medications, the use of a walking device and a higher Katz-ADL 
score. (see Table, Supplemental Digital Content 2; available online)
Table 1: Baseline characteristics 









Age, median (IQR) 79 (74-83) 79 (74-83) 78 (74-83) 0.475
Male, n (%) 732 (48.7) 582 (47.7) 133 (47) 0.111
Living situation, n (%)
   Alone
   Independently with others












   Low









Triage category, n (%)
    > 1 hour (green)
    < 1 hour (yellow)











Arrival by ambulance, n (%) 750 (49.9) 603 (49.5) 147 (51.9) 0.453
The need of hospitalisation, n (%) 688 (45.8) 527 (43.2) 161 (56.9) <0.001
Chief complaint, n (%)
    Minor trauma
    Cardiopulmonary symptoms
    Abdominal pain
    Malaise
    Collapse





















Number of different medications, median (IQR) 5 (3-8) 5 (3-7) 7 (4-10) <0.001
Using a walking device, n (%) 599 (39.9) 442 (36.3) 157 (55.5) <0.001
Katz-ADL, median (IQR) 0 (0-1) 0 (0-1) 1 (0-2) <0.001
Impaired cognition, n (%)* 267 (17.8) 197 (16.2) 70 (24.7)  <0.001
Abbreviations: IQR=interquartile range, n=number
Data incomplete for: educational level (n=1501), the use of a walking device (n=1497), Katz ADL (n=1480), 
abnormal cognition (n=1442). 
* An impaired cognition is considered as an abnormal 6CIT score (≥  11) or a diagnosis of dementia. 
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As shown in Figure 1, three months after follow-up 870 patients had a stable SRH (71.4%), 
140 patients declined in their SRH (11.5%), 67 patients died (5.5%) and in 142 patients 
there was no follow-up SRH available (11.6%). Patients who were not able to provide 
a SRH at three months were older, more institutionalized, use a walking device more 
often, have a higher Katz ADL score and have more often an impaired cognition (see 
Table, Supplemental Digital Content 3; available online). Table 2 shows the association 
between baseline characteristics and a declined SRH three months after an ED visit in 
a multivariable analysis. As shown in Supplemental Digital Content 3 the patients who 
Table 2: The association between baseline characteristics and a declined SRH <6 three months after a ED-
visit.
Variables Multivariable analysis 
oR 95% CI p-value
Age (per 5 years) 1.04 0.87-1.25 0.642
Male gender 1.83 1.18-2.84 0.007
Living situation
        Independently with others
        Alone








Educational level  
        High




    > 1 hour (green)
    < 1 hour (yellow)








Arrival with ambulance 0.98 0.64-1.53 0.954
The need of hospitalisation 1.14 0.75-1.72 0.530
Chief complaint, n (%)
    Minor ref
    Cardiopulmonary symptoms 1.41 0.82-2.41 0.215
    Abdominal pain 1.49 0.74-3.03 0.266
    Malaise 0.69 0.35-1.40 0.307
    Collapse 1.60 0.72-3.54 0.246
    Other 1.59 0.73-3.46 0.244
Number of different medications 1.08 1.03-1.13 0.003
Using a walking device 1.70 1.04-2.80 0.035
Katz-ADL 1.22 1.02-1.47 0.034
Impaired cognition, n (%)* 0.67 0.37-1.22 0.187
Abbreviations: IQR=interquartile range, n=number. The multivariable analysis was done with complete 
data for 964 patients, 255 were missing. * An impaired cognition is considered as an abnormal 6CIT score 
(≥  11) or a diagnosis of dementia. 
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declined in SRH and the patients who had a stable SRH three months after the ED visit 
differed from each other at baseline in several respects. They had a higher age, lived in 
residential care or a nursing home, a higher triage category, presentation with a col-
lapse, a higher number of medications and using a walking device. Also higher Katz-ADL 
scores were associated with a declined SRH after three months. All single items of the 
Katz ADL score were significantly associated with a decline in SRH three months after a 
ED-visit. The OR of these single items were between 1.57 (the use of incontinence mate-
rial) and 4.25 (needing help with transfers). In the multivariable model, the independent 
factors associated with a decline in SHR were: male gender (OR 1.84, 95 % CI 1.19-2.85), 
living alone (OR 1.58. 95 % CI 1.01-2.47), living in residential care or a nursing home (OR 
2.76, 95 % CI 1.21-6.27), number of different medications (OR 1.08, 95 % CI 1.03-1.13), 
using a walking device (OR 1.72, 95 % CI 1.05-2.82) and the Katz-ADL score (OR 1.23, 95 
% CI 1.02-1.48).
Figure 2 shows the difference in mean SRH at baseline and after three months in patients 
with functional decline (n=216, 18.3%) and no functional decline (n=963, 81.7%) three 
months after an ED visit. Patients who experienced functional decline during three 
months after an ED visit, show a steeper decline in mean SRH by 0.68 (SD 2.02) compared 
to patients who did not experienced functional decline 0.12 (SD 1.61), p< 0.001.
We performed a sensitivity analysis in which we defined a decline in SRH as a decrease 
of 2 or more points three months after an ED visit. The univariable analysis shows that 
a higher age, living in residential care or a nursing home and Katz-ADL scores were 
significant associated with a declined SRH with two or more points after three months. 
fig 2: Difference in mean Self-Rated Health (SRH) on baseline and after three months in two groups: pa-
tients with functional decline and no functional decline after an ED visit. 
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However, none of the determinants were independent factors associated with a decline 
in SHR with two of more points after three months (see Table, Supplemental Digital 
Content 4; available online). When assuming that the patients who were not able to 
provide a SRH at three months would have a decline in SRH, living situation, number of 
different medications, using a walking device and Katz-ADL remain independently as-
sociated with a decline in SRH at three months (see Table, Supplemental Digital Content 
5; available online).
DIsCussIon
This prospective study has three main findings. First, determinants of insufficient SRH 
at presentation at the ED were number of medications, using a walking device, Katz-
ADL score and 6CIT-score. Second, predictors of decline to an insufficient SRH during 
three months were male gender, living situation and number of medications. Third, 
the patients with functional decline show a steeper decline in SRH three months after 
follow-up.
Our results are in line with previous literature. Wong et al., described 741 patients aged 
75 years and older attending the ED, made a comparison with the baseline characteristics 
and the different groups of SRH (poor, fair, good, very good and excellent), showing that 
those who rated their health fair/poor at baseline had a lower ADL and cognitive func-
tioning than those rating their health excellent [12]. Furthermore, Chin et al. described 
983 patients aged 65 years and older, and reports that deficiencies in activities of daily 
living at baseline, reports of needing more help with everyday tasks, increasing Charlson 
Comorbidity Index Score and requiring a proxy for the initial survey are predictors of 
poor recovery of Health-Related Quality of Life after an ED visit [15]. The relationship 
between SRH and a decline in functional status is already shown in community dwelling 
older adults [16], in older adults presenting at the emergency department [12] and in 
medical outpatients [17].
Our study shows that patients with a SRH <6 on baseline were significantly different than 
the patients with a SRH ≥6 at baseline. Patients with a SRH <6 were more dependent in 
the daily activities, had a higher 6CIT-score and had a higher number of medication. 
It is imaginable that, when experiencing impairments on multiple domains, the self-
rated health is also low. This is also shown in Spanish institutionalized older persons in 
which chronic conditions, functional status, depressive symptoms and socioeconomic 
factors were the main determinants of self-perceived health [18]. We also show that 
three months after an emergency department visit, patients with a sufficient to good 
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SRH and patients with an insufficient SRH are significantly different with regard number 
of medication, reflecting multiple chronic conditions, and geriatric conditions. In the 
univariable analysis all the geriatric conditions had a significant association with a de-
cline in SRH, and in the multivariable analysis only gender, living in a nursing home or 
residential care home and number of different medications were significantly associated 
with a decline in SRH. We also showed that not the baseline determinants, but a decline 
in functional status is associated with a decline in SRH after three months. This is not 
surprising, since a decline in functional status is usually a reflection of the severity of the 
disease. This is also described in literature that each chronic condition had a significant 
independent effect in a poor SRH and poor QOL [19].
There is a growing interest in quality of life as an outcome in older patients and also 
to maintain quality of life as long as possible. Besides, several literature describes that 
older adults give more importance to quality of live than length of life [20, 21]. Our study 
reports the determinants of an insufficient SRH three months after the ED visit. Future 
research should be focused on ways to intervene on maintaining SRH after an ED visit. 
Recently, a prediction tool was developed for older emergency patients and is usable 
to predict functional decline after an ED visit [4]. When a physician is able to predict 
functional decline, which goes hand in hand with a decline in SRH as our results show, 
physicians should also be able to use preventive interventions and maintain functional 
status and SRH. However, more research is needed to implement this tool and prove its 
use in maintaining functional status and hopefully therewith also SRH.
There are some limitations to our study. First, this study used a modified numeric rat-
ing scale to assess SRH. Ideally we would have used a more comprehensive assessment 
for SRH, for example the EQ-5D exploring five different dimensions (mobility, self-care, 
usual activities, pain and anxiety/depression)[22]. Also other aspects, such as depres-
sion, which is also strongly linked to SRH in different studies [23, 24]have not been in-
vestigated in our study. However, the limited time at the ED restricts the extent to which 
health status can be assessed. Second, during follow-up the proxies were allowed to 
grade the SRH of the patient, which could have made the answer less reliable. However, 
when excluding the SRH giving by a proxy, the overall results did not change, implying 
that the results would not have been different if all patients would have answered the 
questions themselves. In this study the Charlson Comorbidity Index (CCI) is not available 
for most of the patients, as a reflection of comorbidity the number of different medica-
tions is used. The major strength is the unselected representative study population pre-
senting at the emergency department. A second strength is the fact that demographics, 
severity of disease and geriatric vulnerability of the patient were taken into account as a 
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reflection of the condition of the patient. And finally, this is the first study reporting on 
determinants associating with a decline in SRH three months after an emergency visit.
conclusion
In conclusion, decline in SRH after an ED visit in older patients is at least partly depen-
dent on factors of functional capacity and functional decline. Preventive interventions 
to maintain functional status may be the solution to maintain SRH, but more research is 
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This thesis has three key findings. First, only a small proportion of the randomized con-
trolled trials (RCTs) specifically included older adults, and the geriatric characteristics 
in these RCTs are underreported. Second, we show that geriatric impairments, such as 
cognitive impairment and functional dependency, are prevalent, and associate with ad-
verse health outcomes in older patients with head and neck cancer and in patients with 
esophageal cancer. Third, self-rated health is partly dependent on factors of functional 
capacity and functional decline. This chapter reviews these key findings, discusses the 
implications for research and for clinical practice, and provides perspectives for future 
research.
IMPlICaTIons foR ReseaRCh
Increasing the number of representative older adults in research
In chapter 2 we report that only a small proportion of the published RCTs targeted older 
adults. RCTs and meta-analyses are generally considered to provide the highest ‘level of 
evidence’, and the results of these RCTs or meta-analyses are used to compose clinical 
guidelines. Since older adults are underrepresented in these trials and the included 
participants are often not representative for the older adults seen in clinical practice, it 
is questionable whether these clinical guidelines are applicable for older adults. Because 
of the ageing population and the increasing prevalence of multiple (chronic) diseases at 
higher age [1], there will be a need of improving the scientific evidence in older adults. 
To achieve this, several steps should be taken.
Researchers should start to systematically report the geriatric characteristics of older pa-
tients in all RCTs. In chapter 2 we show that geriatric characteristics are underreported, 
even in the RCTs specifically designed for older adults. Consequently, this results in a low 
external validity; i.e. it is unclear to which older adults the results can be applied. Since 
older patients are very heterogeneous with respect to for example, cognitive function-
ing and/or physical capacity, extrapolating research outcomes based on chronological 
age or disease stage alone may lead to undertreatment as well as overtreatment [2, 3]. 
So, when older adults are participating in research, in my opinion, geriatric characteris-
tics should always be reported. Ideally a guideline is available which includes a standard 
set of geriatric characteristics, and that imposes for example, that at least one aspect of 
each geriatric domain should be reported. There is already a guideline available address-
ing ‘physical frailty’ [4]. This could be helpful in characterising older adults in research 
and therewith make the participants comparable between the diverse studies.
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To increase the representative number of older adults participating in RCTs, the RCTs 
should be conducted differently. For instance, by applying less stringent exclusion cri-
teria or by making RCTs more accessible for older adults to participate. One suggestion 
could be to plan home visits, so older (vulnerable) adults are more willing to participate. 
There is already a guideline available on how to perform an RCT in older adults. This 
guideline suggests to combine research activities with routine hospital visits, to plan 
research visits at home or to provide telephone follow up [5]. However, these adaptions 
make RCTs more complex and more expensive, while resources are limited.
Other research methods, like observational studies, may be valuable alternatives 
to consider. Observational studies can generate a large amount of reliable data, are 
easily accessible and often cheaper than an RCT since randomization is unnecessary 
[6]. Besides, observational studies often have less exclusion criteria, and the included 
participants may therefore more broadly represent patients seen in daily practice [7, 8]. 
Furthermore, (international) databases, originally established for improving the quality 
of care, can also be used for research purposes. An example from the Netherlands is 
the Dutch Institute of Clinical Auditing (DICA), which is a registry with information on 
patients and disease characteristics as well as outcomes relevant for patients, such as 
functional performance in the period after a hip fracture. Data from these (international) 
databases may even be combined with local study data. For example, when studying 
geriatric characteristics in patients with esophageal cancer, the study data can be com-
bined with disease and treatment specific information registered in the Netherlands 
Cancer Registry (NCR) database. When studying diseases in older adults, collaboration 
with other institutions in order to increase inclusion rates can be necessary. Major chal-
lenges in these collaborations are the standardization of clinical care and to facilitate 
the systematic registration and collection of data for research purposes. In the future 
perspectives we describe such an initiative.
The importance and the specific aspects of conducting research in older adults should 
firstly be recognized by researchers, clinicians, research grant providers and sponsors. 
This can be achieved by providing more education. One of our initiatives is the develop-
ment an e-learning for medical professionals, but also accessible for non-medical profes-
sionals, about evidence-based medicine in the older patient. All the aspects described 
above (i.e. the importance of conducting research in older adults, the current gaps and 
the needs) are discussed in this e-learning, see also www.iemo.nl/elearning.
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Including relevant endpoints for older adults in research
With increasing age, treatment goals are changing. Compared to younger patients, older 
patients give more importance to quality of life and maintaining functional dependency 
than to length of life [9-11]. Endpoints relevant for patients can be measured using pa-
tient reported outcome measurements (PROMs). In chapter 7 we show that self-rated 
health, one example of a PROM, is partly dependent on factors as functional capacity and 
functional decline. Until now, PROMs are not structurally taken into account as relevant 
outcome in research. One reason is the lack of a “golden instrument” for measuring PROMS 
in older adults. It is not desirable that older adults, often suffer from multiple diseases, 
have to fill several overlapping disease-specific questionnaires. A solution could be one 
standard set of health outcome measures specific for older persons, regardless of the 
disease. The International Consortium for Health Outcomes Measurement (ICHOM), an in-
ternational consortium with goal to increase value-based healthcare, recently developed 
such a standard set [12]. It is debatable if this set is usable in the Netherlands, but it can 
be a good starting point for further investigation of outcome measures that would be 
relevant for clinicians, health care policies and researchers.
IMPlICaTIons foR ClInICal PRaCTICe
In chapter 3, 4 and 5 we report that geriatric impairments are prevalent in patients with 
head and neck cancer and esophageal cancer. The finding that geriatric impairments are 
so prevalent stresses the importance to a more holistic approach of the patient, rather 
than only taking their disease into consideration. Furthermore, geriatric impairments 
might influence the shared decision process. For example, cognitive impairment can 
directly influence the patients’ shared decision making capacity by limiting the amount 
and speed of information processing [13]. The association of geriatric impairments with 
adverse health outcomes is described in diverse patient groups in chapter 3, 4 and 5. 
This finding is in line with literature in other diseases where it has been described that 
geriatric impairments predict several health outcomes including mortality, disability 
and cognitive functions[14].
The discussion above endorses that geriatric characteristics are important to consider when 
making personalized clinical treatment decisions. However, it is remains unclear which 
instrument or tests to explore the geriatric characteristics are the most helpful in treat-
ment decision making or in predicting successful outcomes relevant for older adults. It is 
doubtful that there will ever be one perfect instrument usable and suitable for all different 
diseases and settings. From this thesis it is recommended to start exploring the geriatric 
characteristics as part of routine clinical care instead of waiting for the ‘best’ assessment 
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without taking geriatric characteristics into account at all. Importantly, it is not necessary 
to administer a complete comprehensive geriatric assessment (CGA) to all patients. Several 
two-stepped models have been described in literature, in which all patients undergo a 
short simple screening, and only those with abnormal test scores undergo a complete 
CGA [15]. For example, the geriatric-8 (G8) has a good sensitivity for detecting geriatric 
impairments and for identifying the patients who will benefit most from a complete CGA 
[16]. Taken together, I recommend that all older patients needing an intensive treatment 
should undergo some geriatric screening for example by using a two-stepped model.
fuTuRe PeRsPeCTIVes
We have described several steps that can be taken to improve evidence-based medicine 
and personalized treatment decision making in older adults. The ‘Triage of Elderly Need-
ing Treatment’ (TENT)-study is a good example combining all the described steps. In four 
hospitals in the Netherlands a routine clinical care pathway is implemented for older 
patients (aged 70 years or older), who possibly need intensive treatment (e.g. surgery, 
chemotherapy or radiation therapy or a combination). These patients receive a geriatric 
screening and on indication a comprehensive geriatric assessment prior to the start of 
treatment. We designed the TENT-study based on this routine clinical care pathway. All 
patients are followed for complications of treatment, mortality, functional status and 
quality of life up to 12 months after treatment. The TENT-study has several aims. First, to 
describe the prevalence of geriatric impairments in diverse patient populations need-
ing invasive treatment and to explore the association with outcomes after treatment. 
Second, to develop a tool which can help in making informed treatment decisions and 
to, ultimately, increase the rate of favourable outcomes after treatment and increase the 
quality of care for older patients. The TENT-study started in January 2016 in the LUMC 
and since July of 2018 has been extended into a multicentre study. The first results of the 
TENT-study are expected mid-2019.
The TENT-study exemplifies how geriatric screening can be integrated into the daily 
practice and how to use clinical data in a large multicentre observational study focus-
sing on the older adult needing intensive treatment. This also demonstrates the oppor-
tunities when collaborating with other institutions, standardizing routine clinical care 
and combine it with research. We hope that in the future the format of the TENT-study 
may serve as a template for implementing standardized routine clinical care pathways 
for older adults needing intensive treatment. Ultimately, we hope that the evidence 
gathered by the TENT-study can be used to improve research and evidence-based care 
for older adults needing intensive treatment.
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The world’s population is ageing: almost every country in the world is experiencing 
growth in the number older persons in their population (Eurostat Statistics 2017). With 
increasing age, the  prevalence of disease increases, resulting in a high proportion of 
older adults suffering from multiple (chronic) diseases (also called multimorbidity) [1]. 
Higher age is accompanied with multimorbidity, ageing-associated diseases and is also 
associated with the presence of geriatric conditions. Examples of geriatric conditions 
are: a decreased ability to perform activities of daily living (or functional impairment), 
cognitive impairment, delirium and falls [2, 3]. A way of phenotyping older patients is 
the use of a geriatric assessment. A geriatric assessment is used to explore the different 
domains of somatic status, mental functioning, physical functioning and social function-
ing.
Because of the multimorbidity and the complex interaction between the different 
domains, clinical decision making in older patients can be challenging for clinicians, 
patients and caregivers. It is known that a higher age and multimorbidity are associated 
with many adverse health outcomes such as disability, institutionalization, poorer qual-
ity of life and higher rates of side effects after treatment [4, 5]. However, only few studies 
have assessed the association of a geriatric assessment with outcomes in vulnerable 
older patients with severe diseases, such as head and neck cancer, esophageal cancer 
or end-stage renal disease [5]. Especially in these vulnerable older patients with severe 
treatments can have major impact on outcomes such as disability and quality of life.
aim of the thesis
This thesis has three aims. The first aim is to quantify the lack of evidence in the literature 
regarding the report of elements of a geriatric assessment in older adults participating 
in clinical trials. The second aim is to study the association between the outcome of a 
geriatric assessment and adverse health outcomes in older patients with various severe 
diseases. The third aim is to assess the determinants of a patient reported outcome 
measurement in an older patient population.
summary of the key findings 
In chapter 2, we aimed to evaluate whether it is insightful what kind of older patients 
participated in randomized controlled trials (RCTs). We analysed the published RTCs in 
2012 and evaluated what proportion of trials, specifically designed for older patients, 
reported on elements of the domains of the geriatric assessment in the patient charac-
teristics (i.e. in the population descriptives or the in- and exclusion criteria). We found 
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that only 34% of all trials (participants had a mean age ≥ 60 years) report elements of 
the domains in the patient characteristics. The percentage of reported geriatric domains 
increased when the age limit was higher, however, that only presented a small percent-
age of all included trials. 
In chapter 3 and 4 we studied the association of functional or cognitive impairment, 
social environment and frailty with adverse health outcomes in patients with head and 
neck cancer and in patients with esophageal cancer with a review of the literature. In 
both patient groups we showed that impairment in functional performance, depression 
and social environment were highly prevalent. In patients with head and neck cancer 
the majority of the studies reported a statistically significant association of impairment 
in functional and cognitive performance, mood or social environment with a higher 
risk of adverse outcome. In patients with esophageal cancer, functional or cognitive 
impairment or frailty were associated with adverse health outcomes, but the studies 
were relatively small. 
In chapter 5 we studied the association of geriatric assessment and one-year mortality 
in older patients with cancer in the head and neck region. We analysed the data of a 
cohort study in which all patients aged 70 years and older, diagnosed with head and 
neck cancer, received a geriatric assessment prior to their treatment. We showed that 
geriatric impairments were highly prevalent. Furthermore, we found that the mortality 
rate was high, even in the patient treated with a curative intention. Malnutrition and 
mobility were independently associated determinants with one-year mortality. 
In chapter 6 we aimed to describe in detail the patterns of cognitive functioning and 
identifies nephrologic, geriatric and neuroradiologic determinants associated with an 
impaired cognitive function in older patients reaching end-stage renal disease (ESRD) 
and who have not started with renal replacement therapy (yet). We analysed the data 
from the Cognitive decline in Older Patients with End stage renal disease (COPE) study. 
All patients with end-stage renal disease received a full nephro-geriatric work-up. We 
showed that older patients reaching ESRD have a high prevalence of impaired memory, 
executive function and psychomotor speed. High age, low education, low functional 
status, frailty, higher burden of white matter hyperintensities on MRI and a history of 
vascular disease were determinants. The patterns of cognitive impairment and brain 
changes on MRI are suggestive of vascular cognitive impairment.
In chapter 7, we aimed to identify the determinants associated with self-rated health in 
an older population visiting the Emergency Department (ED). We used the data of the 
Acutely Presenting Older Patients (APOP) study in which a patient reported outcome 
9
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measurement was described in older patients visiting the emergency department (ED) 
of the LUMC or the Alrijne Hospital. As patient reported outcome measurement we used 
self-rated health. We found that a decline in SRH after an ED visit in older patients is at 
least partly dependent on factors of functional capacity and functional decline. 
DIsCussIon
As mentioned previously, only a small proportion of the randomized controlled trials 
(RCTs) specifically included older adults, and the geriatric characteristics in these RCTs 
were underreported. This finding supported our hypothesis that for clinicians it is unclear 
to which older patients the results can be applied. Because of the ageing population and 
the increasing prevalence of multiple (chronic) diseases at higher age [1], there will be 
a need of improving the scientific evidence in older adults. To achieve this, several steps 
should be taken. Researchers should start to systematically report the geriatric char-
acteristics of older patients in all RCTs and make RCTs more accessible for older adults 
to participate. Furthermore, alternative research methods, like observational studies, 
should be considered. However, the importance and the specific aspects of conducting 
research in older adults should firstly be recognized by researchers, clinicians, research 
grant providers and sponsors.
In this thesis we describe that aspects of the geriatric assessment are associated with 
adverse health outcomes. This finding endorses the importance of taking geriatric char-
acteristics into account in patients who possibly need intensive treatment (e.g. surgery, 
chemotherapy or radiation therapy or a combination). Importantly, it is not necessary 
to administer a complete geriatric assessment to all patients. A two-stepped model, in 
which all patients undergo a short simple screening, and only those with abnormal test 
scores undergo a complete geriatric assessment, is suggested[6]. 
An example where all the above described aspects are combined is the ‘Triage of Elderly 
Needing Treatment’ (TENT)-study. In this study all patients who possibly need intensive 
treatment (e.g. surgery, chemotherapy or radiation therapy or a combination), the ge-
riatric characteristics are taken into account and all patients are followed for complica-
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De wereldpopulatie veroudert; bijna ieder land krijgt te maken met een toename van 
het aantal oudere mensen in de samenleving (Eurostat Statistics 2017). Met de toename 
van de leeftijd stijgt ook de prevalentie van ziekten, resulterend in een groter aandeel 
ouderen met meerdere (chronische) ziekten, ook wel multimorbiditeit genoemd [1]. 
Hogere leeftijd gaat samen met verouderingsziekten, multimorbiditeit, en is gerelateerd 
aan geriatrische condities. Voorbeelden van geriatrische condities zijn een verminderd 
fysiek functioneren, geheugenklachten, verwardheid en vallen [2, 3]. In een geriatrisch 
onderzoek worden verschillende domeinen (lichamelijke gezondheid, psychologisch 
functioneren, fysiek functioneren en sociaal functioneren) in kaart gebracht. Hiermee 
kan een inschatting gemaakt worden van het algeheel functioneren van de patiënt. 
De aanwezigheid van multimorbiditeit en de complexe relatie tussen de domeinen, kan 
het maken van behandelbeslissing uitdagend maken voor artsen en patiënten. Het is al 
bekend dat onderdelen van het geriatrisch onderzoek voorspellend zijn voor uitkomsten 
zoals achteruitgang in functioneren, opname in een zorginstelling en een vermindering 
van kwaliteit van leven [4, 5]. Deze relatie is echter nog maar beperkt onderzocht in 
kwetsbare oudere patiënten met ernstige aandoeningen zoals kanker in het hoofd-hals 
gebied, de slokdarm of patiënten met eindstadium nierfalen [5]. Terwijl juist in deze 
patiëntencategorie de behandeling grote gevolgen kan hebben voor uitkomsten zoals 
achteruitgang in functioneren en kwaliteit van leven. 
Doel van het proefschrift
Dit proefschrift heeft drie doelen. Allereerst om het gebrek aan bewijs, ten aanzien van 
het geriatrisch onderzoek en de relatie tot behandeluitkomsten, in de huidige literatuur 
te kwantificeren; ten tweede om te onderzoeken, in verschillende patiëntenpopulaties, 
wat de relatie is tussen het de uitkomst van het geriatrisch onderzoek en de uitkomsten 
na een behandeling en als derde om te exploreren wat de determinanten zijn van een 
patiënt gerelateerde uitkomstmaat in een oudere patiënten populatie. 
overzicht van het beschreven onderzoek
In hoofdstuk 2 hadden we als doel om te evalueren of het inzichtelijk was wat voor 
oudere patiënten deelnamen aan gerandomiseerde studies. Hiervoor analyseerden we 
de gepubliceerde gerandomiseerde studies in 2012 en beoordeelden we of de domei-
nen van het geriatrisch onderzoek werden gerapporteerd in de patiëntkarakteristieken 
(d.w.z. in de populatiebeschrijving of in de in- en exclusiecriteria). We zagen dat er maar 
weinig studies speciaal op oudere deelnemers gericht waren. Daarnaast vonden we dat 
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slechts 34% van alle onderzoeken (waarvan de deelnemers een gemiddelde leeftijd 
van ≥60 jaar hadden) een domein van het geriatrisch onderzoek rapporteerde in de 
patiëntkarakteristieken. Dit percentage nam weliswaar toe naar mate de gemiddelde 
leeftijd van de studie-deelnemers naar boven toenam, maar het ging dan slechts om 
een heel klein percentage van alle onderzochte studies. 
In hoofdstuk 3 en 4  hebben we de relatie van het geriatrisch onderzoek met uitkom-
sten van behandeling in twee verschillende groepen onderzocht; in patiënten met 
hoofd-halskanker en in patiënten met slokdarmkanker. Dit deden we door middel van 
het bestuderen van de bestaande literatuur. We zagen in beide patiëntengroepen dat 
geriatrische afwijkingen, zoals een beperkt functioneren, somberheidsklachten en het 
hebben van geen partner, veel voorkomend waren. Daarnaast zagen we bij de patiënten 
met hoofd-halskanker in de meerderheid van de gevonden studies dat er een relatie 
was met afwijkingen op het geriatrisch onderzoek en slechtere uitkomsten na de be-
handeling. Dit vonden we ook bij de studies naar slokdarmkanker, maar de beschreven 
studies waren relatief klein. 
In hoofdstuk 5 onderzochten we de relatie tussen het geriatrisch onderzoek op de 
verschillende domeinen en de mortaliteit binnen één jaar bij oudere patiënten met 
hoofd-halskanker. We hebben de gegevens gebruikt van een zorgpad in het LUMC 
voor oudere patiënten met hoofd-halskanker. Al deze patiënten kregen een geriatrisch 
onderzoek voordat een eventuele behandeling werd overwogen. We toonden aan dat 
het sterftecijfer erg hoog was, zelfs bij de mensen die behandeld werden met de intentie 
tot genezing. Onafhankelijke voorspellers voor het overlijden binnen één jaar waren 
ondervoeding en mobiliteit. 
In hoofdstuk 6 wilden we het patroon van cognitief functioneren beschrijven en ne-
frologische, geriatrische en neuroradiologische factoren identificeren voor een vermin-
derd cognitief functioneren in oudere patiënten met eindstadium nierfalen. Hiervoor 
zijn de prospectieve gegevens geanalyseerd van vier ziekenhuizen die deelnamen aan 
de “Cognitive decline in Older Patients with End stage renal disease” (COPE) studie. 
Hierbij kregen alle oudere patiënten met eindstadium nierfalen een uitgebreid nefro-
geriatrisch onderzoek. We toonden aan dat er een verminderd cognitief functioneren 
aanwezig was in het geheugen, het executief functioneren en in de in denksnelheid. De 
sterkste voorspellers voor een verminderd cognitief functioneren waren geslacht, lager 
opleidingsniveau, meer afhankelijkheid in het dagelijks functioneren, witte stofafwijkin-
gen op de MRI van het hoofd, en een voorgeschiedenis van vasculaire ziekten. 
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In hoofdstuk 7 onderzochten we factoren die geassocieerd zijn met zelf-gewaardeerde 
gezondheid na een SEH bezoek. We hebben de data van de  “Acuut Presenterende Oudere 
Patiënt” (APOP) studie gebruikt waarin een patiëntgerichte uitkomstmaat beschreven 
werd in een oudere patiënten populatie die de Spoedeisende Hulp van het LUMC of 
het Alrijne Ziekenhuis bezochten. We zagen dat achteruitgang in de zelf-gewaardeerde 
gezondheid na een SEH bezoek op zijn minst gedeeltelijk te verklaren was door factoren 
zoals fysieke capaciteit en achteruitgang in functioneren. 
DIsCussIe
Zoals eerder beschreven zijn er maar weinig gerandomiseerde studies specifiek op 
ouderen deelnemers gericht, en in de gerandomiseerde studies waar oudere patiënten 
wel aan deelnemen is het niet inzichtelijk wat voor type ouderen dat zijn. Deze bevin-
ding ondersteunde onze hypothese dat het voor een arts lastig is om de resultaten van 
gerandomiseerde studies te vertalen en toe te passen op de individuele patiënt in de 
spreekkamer. Omdat er meer ouderen komen met multimorbiditeit [1], is het belangrijk 
om het wetenschappelijke bewijs voor deze groep te vergroten. Om dit te bereiken 
zouden meerdere stappen genomen kunnen worden. Allereerst, om inzichtelijk te 
krijgen wie er aan het gerandomiseerde onderzoek deelneemt, zouden geriatrische 
karakteristieken altijd gerapporteerd moeten worden wanneer er oudere patiënten aan 
gerandomiseerde studies deelnemen. Daarnaast zouden gerandomiseerde studies toe-
gankelijker gemaakt kunnen worden voor oudere patiënten. Tot slot zal er nagedacht 
moeten worden of alternatieve onderzoeksopzetten, bijvoorbeeld observationele stu-
dies, niet meer geschikt zijn om de bewijsvoering voor oudere patiënten te vergroten. 
Echter, het belang van het uitvoeren van onderzoek bij oudere patiënten en de speci-
fieke aspecten moeten in de eerste plaats worden erkend door onderzoekers, artsen en 
subsidieverstrekkers. 
Zoals hierboven beschreven zijn verschillende domeinen van het geriatrisch onderzoek 
geassocieerd met slechtere uitkomsten na een behandeling. Dit benadrukt de noodzaak 
om bij alle oudere patiënten, die een grote behandeling krijgen (operatie, chemothe-
rapie en/ of radiotherapie), de geriatrische domeinen in kaart te brengen. Het is echter 
niet nodig om bij alle oudere patiënten een geheel geriatrisch onderzoek te verrichten, 
er kan eerst een screening plaatsvinden en alleen op indicatie een volledig geriatrisch 
onderzoek [6].  
Een voorbeeld waarbij alle bovenstaande aspecten aan bod komen is de ‘Triage of 
Elderly Needing Treatment’ (TENT) studie. Hierbij worden in alle oudere patiënten 
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die een grote behandeling krijgen (operatie, chemotherapie en/ of radiotherapie), de 
geriatrische domeinen in kaart gebracht. Daarnaast worden ze gevolgd in de tijd voor 
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6CIT  6 Item Cognitive Impairment Test
15-WVLT  15-Word Verbal Learning Test
AC  adenocarcinoma
ADL  Activities of Daily Living
BDI  Beck Depression Inventory
CGA  comprehensive geriatric assessment
CI  confidence interval
CKD-epi  Chronic Kidney Disease Epidemiology Collaboration
COPE-study Cognitive Decline in Older Patients with ESDR study
ECOG  Eastern Cooperative Oncology Group
ED  emergency department
e-GFR  estimated glomerular filtration rate
EORTC  European Organisation for Research and Treatment of Cancer
ESDR  end-stage renal disease
FFI  Fried Frailty Index
GARS  Groningen Activity Restriction Scale
GDS-15  Geriatric Depression Scale 15
GDS-SF  Geriatric Depression Scale Short Form
HADS  Hospital Anxiety and Depression Scale
HNC  head and neck cancer
HR  hazard ratio
HRQoL  health related quality of life
IADL  Instrumental Activities of Daily Living
ICD-10  International Classification of Diseases
IEMO  Institute for Evidence-based Medicine in Old Age
IPAQ  International Physical Activity Questionnaire
IQR  interquartile range
KPS  Karnofsky Performance Score
LDST  Letter Digit Substitution Test
LOS  length of hospital stay
LUMC  Leiden University Medical Center
MDRD  the Modified of Diet in Renal Disease
METC  medical ethics committee
miRNA  microRNA
MMSE  Mini-Mental State Examination
NPTB  neuropsychological test battery
OR  odds ratio
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PRO  patient reported outcome
QoL  quality of life
RCT  randomized controlled trial
SCWT  Stroop Color Word Test
SGA  Subjective Global Assessment
SRH  self-rated health
RRT  renal replacement therapy
RR  relative risk
SCC  squamous cell carcinoma
SD  standard deviation
SPS  Social Provision Scale
TMT-A/B  Trail Making Test A/B
TUGT  Timed Up to Go Test
VAT  Visual Attention Test
WHO  World Health Organization
WMH  white matter hyperintensities
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door de kwantiteit, maar door de kwaliteit ervan. Dat laatste zit bij ons zeker goed! Het 
is fijn om te weten dat we altijd op jullie kunnen bouwen.
Lieve Kim, al jaren ben je mijn allerbeste vriendin en altijd sta je voor me klaar in voor – 
en tegenspoed. Ik hecht enorm veel waarde aan onze vriendschap en het betekent veel 
voor me dat jij vandaag aan mijn zijde staat.
Oma Neele, Oma van Deudekom, Oom Wim en Oma Sabel. Jullie zijn alle vier op eigen 
wijze een inspiratie voor mij.
Lieve Klaas en Simone, dank voor jullie steun, betrokkenheid en interesse. Ik geniet altijd 
enorm van de vrijdagavond waar wij lekker aan kunnen schuiven en de gesprekken die 
we voeren.
Lieve Koen, je zou maar zo’n succesvolle broer als voorbeeld hebben! Ondanks dat we 
elkaar misschien niet regelmatig zien of spreken weet ik dat ik altijd bij je terecht kan, 
dank daarvoor. Ik vind het fijn dat jij vandaag aan mijn zijde staat. Lieve Ada, ik ben 
trots op je hoe jij je promotie hebt afgerond en gelijktijdig thuis de mannen in goede 
banen kan leiden. Na de verhuizing eindelijk ‘rust’? Rens, Jacob Jan, Anna en Florine, 
graag bedank ik ook jullie voor alle gezellige avonden, interessante gesprekken en 
betrokkenheid. Ook Jelle, Wouter, Laura en Francisca wil ik bedanken voor de gezellige 
verjaardagen en andere feestelijkheden.
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Graag wil ik ook mijn ouders bedanken. Lieve papa, mama, Monique en Diederik, jullie 
hebben mij altijd gestimuleerd om mijzelf te ontwikkelen en het beste uit mijzelf te 
halen. Bedankt voor de interesse, de steun en dat jullie er altijd voor mij zijn. Lieve mama 
en Diederik ondanks dat de toekomst onzeker is, heb ik er vertrouwen in dat jullie er het 
beste van maken. Lieve papa en Monique, ook voor jullie ziet de toekomst er misschien 
anders uit dan gedacht, ik bewonder jullie optimisme en wens jullie veel plezier met alle 
toekomstige reizen en plannen.
Ik ben ook trots op jullie!
Lieve Maarten, al meer dan de helft van mijn leven zijn we samen, en nog steeds zo’n 
goed team! Ik kijk uit naar wat de toekomst ons zal brengen. Lieve Mink en Maud, wat is 
het leven met jullie leuk.
